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Identifying Prognostic Gene Signatures Using a Network-Based Approach 
Swetha Bose Nutakki 
The main objective of this study is to develop a novel network-based methodology to identify 
prognostic signatures of genes that can predict recurrence in cancer. Feature selection algorithms were 
used widely for the identification of gene signatures in genome-wide association studies. But most of 
them do not discover the causal relationships between the features and need to compromise between 
accuracy and complexity. The network-based techniques take the molecular interactions between pairs of 
genes in to account and are thus a more efficient means of finding gene signatures, and they are also 
better in terms of its classification accuracy without compromising over complexity. Nevertheless, the 
network-based techniques currently being used have a few limitations each. Correlation-based 
coexpression networks do not provide predictive structure or causal relations among the genes. Bayesian 
networks cannot model feedback loops. Boolean networks can model small scale molecular networks, but 
not at the genome-scale. Thus the prediction logic induced implication networks are chosen to generate 
genome-wide coexpression networks, as they integrate formal logic and statistics and also overcome the 
limitations of other network-based techniques.  
The first part of the study includes building of an implication network and identification of a set 
of genes that could form a prognostic signature. The data used consisted of 442 samples taken from 4 
different sources. The data was split into training set UM/HLM (n=256) and two testing sets DFCI (n=82) 
and MSK (n=104). The training set was used for the generation of the implication network and eventually 
the identification of the prognostic signature. The test sets were used for validating the obtained signature. 
The implication networks were built by using the gene expression data associated with two disease states 
(metastasis or non-metastasis), defined by the period and status of post-operative survival. The gene 
interactions that differentiated the two disease states, the differential components, were identified. The 
major cancer hallmarks (E2F, EGF, EGFR, KRAS, MET, RB1, and TP53) were considered, and the 
genes that interacted with all the major hallmarks were identified from the differential components to 
form a 31-gene prognostic signature. A software package was created in R to automate this process which 
has C-code embedded into it. Next, the signature was fitted into a COX proportional hazard model and 
the nearest point to the perfect classification in the ROC curve was identified as the best scheme for 
patient stratification on the training set (log-rank p-value =1.97e-08), and two test sets DFCI (log-rank p-
value =2.13e-05) and MSK (log-rank p-value = 1.24e-04) in Kaplan-Meier analyses.  
Prognostic validation was carried out on the test sets using methods such as Concordance 
Probability Estimate (CPE) and Gene Set Enrichment Analysis (GSEA). The accuracy of this signature 
was evaluated with CPE, which achieves 0.71 on the test set DFCI (log-rank p-value= 5.3e-08) and 0.70 
on test set MSK (log-rank p-value =2.1e-07). The hazard ratio of this 31-gene prognostic signature is 2.68 
(95% CI: [1.88, 3.82]) on the DFCI dataset and 3.31 (95% CI: [2.11, 5.2]) on the MSK set. These results 
demonstrate that our 31-gene signature was significantly more accurate than previously published 
signatures on the same datasets. The false discovery rate (FDR) of this 31-gene signature is 0.21 as 
computed with GSEA, which showed that our 31 gene signature was comparable to other lung cancer 
prognostic signatures on the same datasets. 
Topological validation was performed on the test sets for the identified signature to validate the 
computationally derived molecular interactions. The interactions from implication networks were 
compared with those from Bayesian networks implemented in Tetrad IV. Various curated databases and 
bioinformatics tools were used in the topological evaluation, including PRODISTIN, KEGG, PubMed, 
NCI-Nature pathways, MATISSE, STRING 8, Ingenuity Pathway Analysis, and Pathway Studio 6. The 
results showed that the implication networks generated all the curated interactions from various tools and 
databases, whereas Bayesian networks contained only a few of them. It can thus be concluded that 
implication networks are capable of generating many more gene or protein interactions when compared to 
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Lung Cancer is caused due to the uncontrolled growth of cells in the tissues of lungs. It is critical 
to identify gene signatures that can predict cancer recurrence to improve patient care. Genes 
having high degree of connections with the major cancer markers have strong impact on the 
network topology [7] and are thus the critical genes of the network. There are different 
techniques which can identify these critical genes. 
Feature selection techniques have been used earlier to find prognostic markers from a group of 
data by eliminating genes which have little or almost no predictive information [47]. These 
techniques were used in machine learning particularly for the purpose of removing irrelevant or 
redundant features from data and forming a subset of relevant features. Though feature selection 
techniques have a good number of advantages, they still have a few limitations. When there are a 
large number of features, the search for a good subset of features (which provides optimal 
results) becomes very complicated and tedious. Moreover feature selection techniques consider 
the behavior of genes individually which might not act in the same manner in the presence or 
absence of other genes. 
Network-based techniques can be used to find gene signatures and overcome the limitations of 
feature selection methods. Network-based techniques work in uncovering the causal 
relationships between the genes and are also better in terms of stability and classification 
accuracy [7] and thus they are an efficient means of finding prognostic gene signatures when 
compared to feature selection algorithms. They consider the signature of genes as a whole 




between pairs of genes. This works well as genes might not act in the same way when they are 
alone and when they are acting along with other regulators. Network-based techniques are more 
useful in cases where huge datasets come into picture [8]. This is due to the fact that performing 
an exhaustive or complete feature selection technique on a huge dataset would be very time 
taking and also requires a lot of resources. Most of the lung cancer datasets are huge and thus 
using these network techniques helps in identifying signatures faster and in an accurate manner 
and it also helps in analyzing the signatures in a better way. 
Currently, there are different network-based techniques that are in use such as coexpression 
network, Bayesian network, and artificial neural network. Though these network-based 
techniques overcome the limitations of feature selection methods, they still have a few 
limitations each. Correlation-based coexpression networks are inconsistent as their accuracy 
decreases with increase in network size [7]. Bayesian networks cannot model feedback loops and 
their complexity increases exponentially with the number of genes in the network [4]. Artificial 
neural networks are very complex and time taking in nature. Moreover to our knowledge, neural 
networks have not been used for modeling molecular interactions yet.  
To overcome the limitations of the currently used network-based techniques, implication 
networks based on prediction logic were chosen to generate the genome wide networks [2]. The 
methodology used in implication networks is computationally manageable for analyzing large 
datasets and integrates formal logic and statistics [1], thus making it more efficient. 
To generate the genome wide networks based on prediction logic [2], the gene expression data 
(from University of Michigan Cancer Center (UM) and Moffitt Cancer Center (HLM) together used as 




group and non-metastasis: corresponds to the low risk group) based on the survival period and 
survival status. The genome wide networks of both the groups were compared and the common 
interactions they have were removed. Thus we could focus on the differential components in 
networks that remained which are the interactions that differentiated the metastasis group from 
the non-metastasis group.  
To identify prognostic signatures, major cancer hallmarks such as E2F, EGF, EGFR, KRAS, MET, 
RB1, and TP53 were considered and the genes that interact with all these major cancer hallmarks 
were considered to form a signature. The hallmark E2F had many probes like E2F1, E2F2, E2F3, 
E2F4, and E2F5. These probes can be picked in various combinations depending on their 
functionality. Thus different sets of hallmarks can be considered. Different signatures can be 
identified by varying the set of hallmarks used to pick the genes. Thus different gene signatures 
were identified based on the interactions between the genes and the hallmarks under diseased 
conditions. 
To identify the most prognostic signature from the obtained signatures, survival analysis [35] 
was done using techniques such as Time-dependent ROC [16] (statistical p-values and area 
under curves (AUC) over time were used as measures to compare the different signatures), 
Random testing (different signatures as the same size of the identified signatures were picked 
randomly and checked where our signature stands among the randomly picked signatures), and 
COX proportional hazard model [18, 19, 28] (Kaplan-Meier plots and log-rank test results were 
observed). For analysis with COX proportional hazard model, both univariate (considering the 
gene expression values of the genes only) and multivariate analysis (considering the risk scores 
of the signatures as a predictor and comparing with other predictors such as age, gender, 




were used for determining the significance of the signature in differentiating the two groups from 
one another. Log-rank p-values were observed from the COX proportional hazard model and 
signature was picked which had values less than 0.05 for training and test sets, showing it to be 
significant. Multivariate analysis using the COX proportional hazard model was done as a part of 
the evaluation of the signature with respect to other clinical parameters. 
To validate the signature obtained, both prognostic and topological validation was performed on 
the test datasets (from Memorial Sloan-Kettering Cancer Center (MSK) and the Dana-Farber Cancer 
Institute (CAN/DF) [20]). The prognostic validation was conducted using techniques such as 
Overall Accuracy [32], Concordance Probability Estimate (CPE) [29], and Gene Set Enrichment 
Analysis (GSEA) [30]. Sensitivity and specificity were measured along with the overall accuracy 
values. CPE was used to evaluate the distinguishing power and the predictive accuracy of the 
statistical model. CPE measures included the statistical log-rank p-values, hazard ratios, and 95% 
confidence intervals which were compared with published signature from Shedden et al [20]. 
The results showed that the 31-gene signature had more significant statistical p-values, higher 
hazard ratios, and higher CPE values which confirm that the signature is better when compared 
to the other published signature. GSEA is a powerful analytical method that computed whether 
the 31 gene signature is statistically significant and whether the gene set has agreeable 
differences between the two phenotypes (biological states). GSEA was used to compare our 
signature with many other previous signatures using False Discovery Rates (FDR) and 
Normalized Enrichment Scores (NES). GSEA results showed that the signature had FDR < 0.25 
which makes it significant. The comparisons above showed that our signature was either 
comparable or better than the other signatures on the same datasets. 
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To topologically validate the gene signature, the interactions from implication network were 
compared with interactions from Bayesian network generated by Tetrad IV1. Then various tools 
such as Prodistin2, KEGG3, NCI4 pathways, PubMed5, Matisse6, String7, Ingenuity Pathway 
Analysis8, and Pathway studio9 were used. These tools extracted their interactions from various 
sources such as literature, curated databases, etc. All the interactions found from the above 
mentioned tools were compared with the interactions generated from implication network and 
interactions from Tetrad IV (Bayesian network). 
From the interactions extracted from various biomedical tools, it was concluded that implication 
networks are capable of generating many more gene or protein interactions which were validated 
by the molecular interactions from other tools when compared to the Bayesian networks. The 
functional classes identified from the signature reveal that the genes are not just structurally 
connected but also have biological relationships. Thus these genes could be focused in predicting 
cancer recurrence in therapeutic conditions. 
The chapters in this thesis are as divided as follows. The second chapter provides literature 
review of the currently used techniques. It also provides descriptions of all the methods and web-
based tools used in this study. The third chapter describes the methodology used to identify the 
gene signature from the genome wide coexpression networks. The fourth chapter discusses the 
results obtained from prognostic and topological validation techniques. The fifth chapter 




also describes the versions of the editors and the configuration of the system used to run the 
analyses. The sixth chapter concludes all the above mentioned chapters and also includes the 







This chapter describes various techniques to identify signatures. Feature selection methods are 
described in brief followed by their limitations. These limitations are overcome by introduced 
network-based techniques. Different network-based techniques currently used such as 
correlation-based coexpression networks, Bayesian belief networks, and artificial neural 
networks are discussed followed by their limitations which are overcome by the implication 
networks. The implication networks are discussed and the algorithm which has been used to 
induce the implication networks is discussed. Different validation techniques which have been 
used to validate the signature found from implication networks were discussed. Finally a 
summary of the entire chapter is given. 
2.2 Different techniques to identify signatures 
There are different procedures to identify gene signatures. Potential markers have been screened 
earlier by identifying the overexpressed or the underexpressed genes. But this process is not 
good enough as the information of each individual gene is considered when the interactions 
between genes were supposed to be considered [15]. 
Feature selection [47] techniques have been used earlier to find prognostic markers from a group 
of data by eliminating genes which have little or almost no predictive information. These 
techniques were used in machine learning particularly for the purpose of removing irrelevant or 




the curse of dimensionality by reducing the number of features that have to be considered and 
thus speeding up the process. They can be used with both supervised (to produce high 
classification accuracy) and unsupervised learning (to find good subsets of features that form 
quality clusters). Though feature selection techniques have several advantages such as removal 
of redundant and irrelevant features, improving the classifier performance, etc., they still have a 
few limitations. When there are a large number of features in the beginning, as in the case of 
lung cancer genes, feature selection techniques become very complicated and it becomes tedious 
to find a good subset of features. Moreover they consider the genes individually which might not 
act in the same manner in the presence or absence of other genes. 
The most important advantage of network-based approaches over feature selection methods is 
that they can capture and represent more complex types of relationships among genes or any 
variables of interest [8]. Since there will be a large number of relationships between genes, 
methods other than network-based procedures become more complex and the computation of 
such models becomes very tedious (for example, in case of feature selection methods, optimal 
output requires exhaustive search which is very time consuming). Network-based techniques 
help in revealing the underlying molecular mechanisms related to the genes. Networks built with 
genes can be used to identify disease mechanisms [34] and for drug discovery [33], and also for 
identifying prognostic subnetworks which lead to metabolic pathways [33]. Other methods (such 
as feature selection techniques) ignore genes which do not have significant differential 
expression individually in different classes but which actually play vital roles as a member of a 




Gene networks are constructed in such a way that any pair of genes are connected if some 
measure (calculated from the current conditions of the genes) related to both the genes exceeds a 
given threshold [13]. 
There are many network-based approaches that are already in use for classification analyses and 
for identifying interactions between genes. Some of them are described below. 
2.2.1 Coexpression Network 
Gene coexpression network connects genes with similar expression profiles (such as the Pearson 
correlation coefficient [15] or the clustering coefficient [13]) and thus connects functionally 
related genes [13, 15]. This network tries to investigate the transcriptional changes in terms of 
“gene interactions” rather than at the level of “individual genes”.  
Pearson correlation coefficient measures the degree of linear dependence between two time-
courses of gene expression levels [14]. It is close to one when there is good correlation between 
the time series. It is near negative one when there is negative correlation and is close to zero 
when there is no correlation between the expression values [42]. It can be calculated as shown 
below. If  stands for correlation between the genes  and ;  and  are the gene 
expression values of genes  and  respectively;  and  are the means and  and  are the 
standard deviations of the genes   and  respectively;  is the total number of genes; then 








Hence Pearson correlation ( ) was calculated for each dataset and was converted in to a standard 
normal metric using the Fisher’s transformation [15]. This standard normal metric shown below 




1  (2.2) 
Clustering is generally used to cluster (group) genes based on a correlation-based distance 
measure quantifying the degree of co-regulation [14]. Thus the function of an unknown gene can 
be predicted from the known functions of other genes present in the same cluster [14]. Clustering 
algorithms work well when the genes are co-regulated. Gene expression clusters can also be 
mapped on to metabolic networks in order to discover pathways of interest. The clustering 
coefficient of gene  is denoted by  and is calculated as shown below. If  is the number of 
first neighbors of gene  and  is the number of edges between the  first neighbors, clustering 
coefficient of the entire network can be calculated by taking the average of the clustering 
coefficients of all the genes in the network as shown below. 
 2
1  (2.3) 
The underlying postulation of the network distance metric is that the enzymes are related 
according to their proximity in the network. If this metric is above a specific threshold, the pair 
of genes would be connected. It considers that a rise or fall in the correlation of a gene pair might 
be associated with the upregulation or downregulation of other genes in the same functional 
cluster. These networks constructed from pair-wise correlation coefficients have provided a 
productive procedure to recognize functional transcriptional modules related with specific 




Aoki et al. [6] explored the gene co-expression networks in plant biology and concluded that co-
expression network analysis provided innovative awareness in the system level understanding of 
plant biology. In many cases, gene co-expression networks implied the presence of functional 
linkage between genes associated with biological processes. 
L.L. Elo et al [13] proposed a systematic approach for the estimation of the threshold of 
coexpression networks directly from their topological properties. They used the clustering 
coefficient for the threshold selection which when gradually increased reduced the number of 
links from the initially complete graph of coexpression networks. They experimented on the 
simulated data generated using the stochastic model of Thalamuthu et al [49] which consisted of 
60 datasets. The biological relevance of the coexpression was investigated by the p-values. 
Hanisch et al. [14] proposed the construction of a distance function (correlation-based distance 
function) which combined the information from biological networks (in an integrated manner) 
and gene expression data. They focused on the analysis of co-regulated metabolic pathways 
which were supported by gene expression measurements. They calculated the Pearson 
correlation coefficient on log-ratio transformed data and then converted it in to a distance metric 
which quantified the degree of dissimilarity of their gene expression dataset. They defined a 
graph distance function on the networks and combined it with correlation based distance function 
for gene expression measurements. They conducted the experiments on the organism 
S.cerevisiae (yeast).  
Choi et al [15] introduced a model (mentioned above using Pearson correlation coefficient and 
its Fisher transformation to find effect size) for finding the differential coexpression from 




published gene expression datasets from cancers of 13 various tissues and built 2 different 
coexpression networks, a tumor network and a normal network which were compared.  
S. Tornow and H. Mewes [41] proposed a technique which was based on collective, multi-body 
correlations in a genetic network. They calculated the correlation strength of a group of genes in 
a coexpression network which were identified as members of a module in another protein 
interaction network and estimated its correlation probability.  
Zhang and Horvath [43] proposed a general framework for soft thresholding which assigned a 
connection weight to each gene pair. They used several adjacency functions (such as sigmoid 
function, power adjacency function, etc.) to convert the correlation coefficients to connection 
weights. They experimented on simulated data, a cancer microarray dataset and a yeast 
microarray dataset.  
Thus coexpression networks have been used in several applications such as for discovery of 
genetic modules, applying to human T helper cell differentiation process [13], for topology based 
cancer classification [7], for molecular characterization of cellular state, etc. 
There are a few limitations of coexpression networks. Correlation-based coexpression networks 
are based on similarities and clustering based coexpression networks are based on the distance 
measures. Thus they do not provide a predictive structure and do not infer causal relationships 
among genes. High correlation is exhibited by genes when the entire set of expression patterns 
across different conditions is similar. On the other hand, high correlation is also exhibited by 
genes if they are expressed together under a few conditions and are otherwise silent [6]. 
Moreover the accuracy of correlation-based coexpression networks decreases, as the network 





The Bayesian networks model is a causal network which represents the joint probability 
distributions. Bayesian networks are useful for describing complex probabilistic models which 
require learning from noisy observations. Bayesian Networks are thus capable of estimating the 
confidence in different features of the network and thus are a promising tool for examining gene 
expression patterns [4]. 
If we have a finite set of random variables, , … , , where  is a variable which might 
take values from the domain Val( , Bayesian networks are represented using joint probability 
distributions consisting of two components, , ; a directed acyclic graph [4] (DAG)  
(whose vertices correspond to the random variables, ) and a conditional distribution for each 
variable  (given its parents in ). According to Markov assumption, each variable  is 
independent of its non-descendents, given its parents in  and their joint probability distribution 
can be defined as below [4]. 
 
, … ,  (2.4) 
Here    is the set of parents of  in . Once networks are built, they are needed to be 
scored by some means so that the networks are evaluated and the optimal network can be found. 
Posterior probability can be used to evaluate the graphs. If a large number of networks are given, 
learning procedures can pinpoint the exact network structure which has best dependencies in the 
distribution.  
Bayesian Networks were used to describe the interactions between genes in a paper by Friedman 
et al. [4] where they described a method to recover the gene interactions from microarray data. 
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They also applied the method to the S.cerevisiae cell-cycle measurements of Spellman et al. 
(1998). They used priors described by Heckerman and Geiger (1995) for hybrid networks of 
multinomial distributions and conditional Gaussian distributions.  
It has been described by Friedman et al. [4] that a causal network models the distribution of the 
observations as well as the effects of interventions.  and  are equivalent in Bayesian 
networks but they are not equivalent in causal networks. If  causes , then changing the value 
of  affects the value of . But it is not true the other side, i.e., changing the value of  does not 
affect the value of . Their approach was to analyze a high number of high scoring networks 
which requires an efficient learning algorithm such as the Sparse Candidate algorithm. To relate 
their analysis with the biological phenomena in the data, they used the order relations and 
Markov relations found from their data. 
As Bayesian networks have the capability of working even in highly noisy surroundings, it has 
many real-world applications. Some of them in bioinformatics are for building gene regulatory 
networks and protein structures [34]. They are also applicable to other fields such as medicine, 
image processing, information retrieval, etc. 
There are a few limitations to the Bayesian network approach. Since the Bayesian networks are 
directed acyclic graphs, the probabilities of the child nodes are calculated from the parent nodes. 
Thus Bayesian networks cannot have loops and they also require a subjective prior (for the first 
parent node). Bayesian networks need complete knowledge of the real-world in order to build the 
correct causal model. These networks are expensive to compute and the rate of complexity 
increases exponentially with the number of genes present in the network [8]. Thus they become 
more impractical and inappropriate. 
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TETRAD IV11 and its search algorithms were developed with the support of National 
Aeronautics and Space Administration and the Office of Naval Research. TETRAD IV is a 
program for working on causal/statistical models particularly Bayesian belief networks. It is used 
for creating, simulating data from, estimating, testing, predicting with and searching for causal 
models. It has a friendly interface and no programming knowledge is required to use it. It is 
unique in the suite of principled search algorithms. 
A program description of a causal model is done in three stages in TETRAD IV. The first one is 
a picture which uses a directed graph to state in detail the hypothetical causal relations among 
variables. The second stage would be to specify the family of probability distributions and the 
kinds of parameters associated with the graphical model. The final stage would be to specify the 
numerical values of the parameters explained earlier. 
Sessions in TETRAD IV are built by dragging boxes in to the workspace and then connecting 
them with arrows in legal ways that represent their dependencies. The Figure 2-1 below shows 
the model used in TETRAD IV to build Bayesian networks. This network was compared to the 




Figure 2-1: Model used in TETRAD IV showing all the boxes 
 
Data box: 
We use data that was loaded from an external file. Here “Data set” list is a record of available 
datasets, where one of the lists is considered as “selected”. There are three types of data that can 
be stored in the data set list namely: Tabular data set, Covariance matrix, and Correlation matrix. 
We use Tabular data set. The Data wrapper is shown in Figure 2-2 below. 
 






TETRAD IV has a variety of search algorithms to assist in searching for causal explanations of a 
body of data. The search algorithms read in data and return information about a collection of 
alternative causal graphs that can explain features of the data. Some search algorithms can often 
predict whether a particular variable influences another or not. Search algorithms do not output 
an estimated model with parameter values; instead they output a description of a class of causal 
graphs that explain statistical features of the data which were considered by the search 
procedures. Some of the search procedures available are PC, CPC, PCD, FCI, etc which are 
shown in Figure 2-3 below. We use PC technique which searches for Bayes net or SEM models 
when it is assumed there is no unrecorded variable that contributes to the association of two or 
more measured variables. The output obtained after execution of PC search algorithm is shown 
in the Figure 2-4 below.  
 
Figure 2-3: Available Search Algorithms 
 
 




Parametric Model Box: 
A parametric model specifies the family of probability functions connecting cause and effect, but 
does not specify values for its parameters. Two types of parametric models can be created using 
TETRAD IV namely Bayes and SEM. If Bayes net is chosen, then the input graph to the PM box 
will be parameterized as a categorical model in which the parameters are the unspecified 
conditional probabilities of values of each variable on the values of its parent variables in the 
graph. Bayes PM takes a DAG and adds to it, two bits of information (the number of categories 
and the list of categories). If SEM is chosen, then the graph will be parameterized as a linear 
Gaussian model with variances and linear coefficients. The Bayes PM is shown in the Figure 2-5 
below. 
 
Figure 2-5: Bayes Parametric Model 
 
Estimator Box: 
The Estimator box takes in information from the Parametric Model and the Data and outputs an 
instantiated model. The procedures in the statistical estimator allow estimation of the parameters 
based on the input data. Types of estimators include ML estimator, SEM estimator and Dirichlet 
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estimator. There are also procedures for handling missing values in the input data. The ML 
Bayes estimator is shown in the Figure 2-6 below. 
 
Figure 2-6: ML Bayes Estimator 
 
Instantiated Model Box: 
An Instantiated model specifies particular numerical values for the parameters of a parametric 
model. There might be three types of instantiated models namely Bayes instantiated model, 
Dirichlet Bayes instantiated model, and SEM instantiated model. A Bayes instantiated model 
extends a Bayes parametric model, specifying values of the parameters in the Bayes net. The 
parameters for a Bayes net are the conditional probabilities stored in the conditional probability 
tables, one for each variable in the Bayes net. The Bayes instantiated model is shown in the 




Figure 2-7: Bayes Instantiated Model 
 
Classify Box: 
A Classifier box requires input from the Data and from IM box. It is used to classify new cases 
with the Bayes net in the IM box. The user specifies a target variable in the IM and the classifier 
uses the Bayes net structure of the IM to predict the values of the target in the data set. Statistics 
on the classification accuracy are provided as ROC curves (shown in Figure 2-8), AUC and 




Figure 2-8: ROC curve after classification 
 
Figure 2-9: Confusion Matrix after Classification 
 
2.2.3 Artificial Neural Network 
Artificial neural networks are computing systems which try to mimic the elements and structures 
of the nervous system in a summarized manner [50]. They were actually developed as a better 
means of understanding the human brain and then they were used for roles like optimization [9]. 
In other words, if a neural network is given a large set of information, it can generalize from that 
data by learning about it (training). This network is built on the strategy of train, test, 
differentiate, and retrain on reduced gene set and then retest [10, 12].  
An artificial neural network is a group of nodes and lines between the nodes where each node 
depicts a neuron and the lines depict the relationship between the neurons. Strength of each 
relationship is defined by a variable on which threshold can be applied to remove insignificant 
relationships. These nodes and their interconnections are organized as layers. There will be an 
input layer (to which the input is presented), a hidden layer (where all the processing is done on 
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Figure 2-11: Training and Prediction Phases in a model built with Artificial Neural Networks [10] 
 
Neural networks are particularly useful for classification analyses that are highly tolerant to 
precision errors [11]. They can be used as alternatives to approaches which are limited by 
assumptions of normality and linearity.  
Good man and Harrell [9] discussed the advantages and limitation of using neural networks for 
biostatistical modeling. They compared the neural network model with the generalized linear 
model which is another popular biostatistical method. They found out that for binary outcomes 
such as survival, cancer recurrence, etc. a link function is required to monotonically constraint 
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the output prediction. The neural networks had efficient dimensional scaling but they had an 
increased computational burden to optimize the model. 
Boger [44] demonstrated the application of artificial neural networks for gene array analysis and 
cancer cell identification. The data was first trained using a Principal Component Analysis 
training algorithm and then local minima avoidance and escape algorithms were used. The inputs 
were then ranked according to their relevance to the artificial neural network prediction accuracy 
and the least relevant inputs were discarded. The remaining set of inputs was retrained to get 
better prediction accuracy and this process is repeated. 
Xu et al [45] discussed the method of distinguishing between two kinds of cancers using 
artificial neural networks and gene filtering. In this method, the data was first clustered and it 
was filtered using SAM gene filtering. The artificial neural network was then constructed based 
on the principle of FeedForward with Error Backpropagation. 
Keedwell et al [46] discovered a neural-genetic method which combines a genetic approach with 
a supervised single layer artificial neural network to form a hybrid system. In this approach, they 
formed a training set on which the gradient descent algorithm was applied via the artificial neural 
network to determine the weights between the input genes and the output genes. The output is 
tested for errors and the process is repeated until the errors meet the stopping criterion. They 
experimented on the yeast S.cerevisiae data which consisted of 2468 genes. 
Neural networks have been widely spread in various fields [9] such as pattern recognition, 
speech synthesis, robotic control, etc. They can also be used to identify most relevant genes from 




Neural networks have a few limitations. Neural networks need a very huge training dataset to 
generalize. If the dataset is not sufficiently large enough, the network model will be biased. They 
cannot be used for data which do not have any correlation among the variables present in the 
data. Moreover these networks need a lot of iterations to reach an approximation with minimum 
errors. Since the iterative process is a time taking procedure, the amount of time required for 
different networks is not always the same and hence it is a major shortcoming of neural 
networks. Sometimes the neural networks might be over-trained which might lead to good results 
only in the training but which actually don’t work for the test datasets. Neural networks are 
difficult to understand and are not easily extensible. Neural networks are considered to be black 
boxes [44] as the process that is going on in the hidden layer is not known to the user. Moreover 
many applications of artificial neural networks include classification analyses but to our 
knowledge, there are no applications for the complete modeling of gene-gene interactions yet. 
2.2.4 Boolean Networks 
Boolean networks are a kind of dynamic networks which are used to model gene regulatory 
networks. 
Sahoo et al [3] proposed a method for extracting the Boolean implications from large microarray 
data. They analyzed the data from three species: humans, mice and fruit flies. They tried to 
capture new relationships that were preserved in all the three species in spite of the differences in 
various factors like tissue difference, gender differences, etc.  
Boolean networks are limited to small scale networks. Since they are dynamic networks, it 
becomes very difficult to model them at genome scale. This is due to the exponential increase in 




Since all the above mentioned network-based approaches have a few limitations, another type of 
network called the implication network is considered to build the interactions between the genes. 
The algorithm to induce an implication network was first developed by Liu et al [1]. This 
algorithm was based on binomial distribution. An alternative algorithm to induce the network 
(which can be used not just with binomially distributed data as mentioned by Liu et al [1], but in 
general to all implication networks built on either binomial or non-binomial data) was developed 
by Guo et al [2] which was based on prediction logic.  
Liu et al [1] described an algorithmic means for inducing implication networks from empirical 
data samples. Several Monte-Carlo simulations were conducted to examine the effectiveness and 
validity of the induction method. Dempster-Shafer belief updating scheme was used to predict 
the values in implication networks.  
Guo et al [2] proposed a novel methodology for predicting fault prone modules by using 
Dempster-Shafer methodology. This methodology was applied on two case studies based on 
NASA datasets and the performance of the methodology over other analyses was observed. The 
prediction logic induced network in this paper has been used to build the implication networks 
for our study. 
In spite of the existence of many other network-based techniques, Implication networks were 
used for this study. This is because they overcome the limitations of various other network-based 
techniques. Implication networks are better than correlation networks in the sense that most of 
the interactions between the genes in implication networks have comparable correlation 
coefficients [3]. Thus it can be concluded that gene pairs with high correlation coefficients are 
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almost always present in implication networks [3]. In addition, the accuracy of the correlation 
networks decreases with increase in the size of the network and they cannot tolerate noise 
accumulations. Thus gene networks with implication relationship are superior to those with 
correlation relationship in terms of accuracy and stability of the classifier performance [7]. 
Moreover computing an implication network is not time taking as in the case of the neural 
networks. They are simple to construct and are fast in terms of computation. The implication 
networks do not need any prior learning regarding the implications, and their complexity does 
not increase in an exponential manner and thus they overcome the limitations of Bayesian 
networks. 
A graph which involves nodes and arcs connecting each of the nodes in a directed manner is 
called an implication network. In this network, each node represents a variable which might be a 
gene or protein. Each arc between the nodes indicates the presence of a relation (a direct 
implication like influence, binding, regulation, etc.) between the nodes (genes or proteins) it 
connects. These arcs relate the values of each node with its parent nodes and child nodes and 
these values are updated at regular intervals. The arcs are accompanied by weights which 
represent the strength of the node relationships.  
Contingency tables [2] are a tabular representation of categorical data which are used to record 
and analyze the relationship between two or more variables. Thus it represents the strength of 
association among the variables. In our network we used the contingency table to represent the 
occurrences of errors in samples that are associated with the six possible implications.  
An implication can be defined in the following manner [1, 2]. For , If A is True, then B 
is also True. If A is False, then B can be either True or False. So the erroneous case for  
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would be A being True and B being False. This is shown below as positive implication in the 
Figure 2-12 with a shaded cell. Similarly for , the erroneous case would be both A and 
B being True, which is shown as forward negative implication in Figure 2-12. Similarly inverse 
negative implication and negative implication can be understood. For , A and B should 
both be True or both be False. So it combines the positive implication and the negative 
implication to form the positive equivalence. Similarly for , A and B should be 
opposite to one another. This combines the forward negative implication and the inverse negative 
implication to form the negative equivalence. Thus all the six relation types can be explained.  
 
Figure 2-12: Six possible implications relating two variables [2] 
 
The Contingency table that was used to calculate different values is shown below in Figure 2-13. 





Figure 2-13: Contingency Table 
 
The implication induction algorithm is shown in Figure 2-14 which was taken from Guo et al. 
First significance level  and a minimal  are set for each  , 0, 1  and 
, 1, . Here  is the total number of attributes. Contingency table is 
computed for all the possible sample cases and     that satisfy the condition on  is 
computed for all relation types. This process is iterated till a solution exists and once a solution is 




Figure 2-14: Implication induction algorithm from Guo et al [2] 
 
In this algorithm,  and   correspond to  and  respectively in our project. 
They are the minimum scope and minimum precision that are required for the implication rule to 
be considered as significant. They are calculated from simple Z-test for a cutoff value of 1.64 . 
These values keep varying with the number of samples in the group. 












 1  (2.9) 
 1  (2.10) 
 1  (2.11) 
 1  (2.12) 
The first four values of  relate to each of the unsymmetrical implications. The values of  
for symmetrical implications can be found by combining values of two each of the 





The implications are associated with two weight functions that specify the strength of the 
relationship between the pair of nodes that are connected. These weight functions can thus be 
defined as shown below [1, 2]. 
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 0,1  (2.15) 
 0,1  (2.16) 
Thus they can be defined in terms of the contents of the contingency table as below. 
  (2.17) 
  (2.18) 
Thus if  is a complete set of possible implication rules which can be generated,   is the relation 
type,  and  are the weight functions that map the precedent node   and the consequent 
node , then an implication rule can be generalized as follows [2]. 
 , , , , ,  (2.19) 
Implication networks extract many more relationships among the variables that are overlooked 
by most of the current approaches. Most of the currently existing approaches concentrate only on 
the relations which have same states for both the variables like in the cases of positive 
equivalence and negative equivalence. But there might be some very significant connections in 
the implication networks which are not significantly correlated. The implication networks have 
the capability to identify many known biologically phenomena and also to extract hierarchical 
relationships. They are also stable over various species.  
2.4 Survival Analysis 
To validate the prognostic signatures identified in the network-based approach, survival analysis 
is performed on them. Survival Analysis is normally done with respect to the occurrence of an 
 
33 
event (which is normally death of the patient) with time. It helps in finding out what portion of 
the considered group survives past a certain time. It also gives the rate of increase or decrease of 
the occurring event. Survival Analysis is done using the following methods 
1. Time dependant ROC analysis and Random Test 
2. Cox Proportional Hazards Model 
3. Kaplan-Meier Plots 
4. Multivariate Analysis using Cox Proportional Hazards Model 
2.4.1 Time dependent ROC analysis and Random Test 
ROC curves are techniques used for visualization, organization, and selection of classifiers based 
on their performance. They are plots between sensitivity and (1-specificity). Time dependent 
ROC analysis is said to be done when ROC (Receiver Operating Characteristics) curves are 
varied as functions of time . Since most of the disease outcomes are dependent on time, Time 
dependent ROC analysis becomes more apt.  
ROC curves are capable of portraying the differentiation capacity of a test even without 
considering a specific threshold [16]. Even when the diagnostic markers are on diverse scales of 
measurement, ROC curves provide a convenient method for comparison. AUC or the Area under 
the Curve [17] is also considered as an important standard of comparison. It can be considered as 
the metric that compares the probability of diseased states to non-diseased states and thus 
summarizes the ROC curve. Since ROC is a two-dimensional representation of the classifier 
performance, it can be reduced to a single scalar value as AUC representing the expected 
performance. Thus realistic classifiers should not have AUC value less than 0.5. Since ROC 
graphs are conceptually very simple, they can be used as cost-sensitive learning techniques. 
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If  is the explanatory variable or predictor, and  is the event (which is death in our case) at 
any time . If a cutoff point  is considered which keeps varying, then the sensitivity and 
specificity would be functions of  and . Thus the sensitivity and specificity can be expressed as 
[16] 
 , | 1  (2.20) 
 , | 0  (2.21) 
Thus  curve is a graph plotted between ,  (it is the Y-axis in the ROC 
curve) and 1 ,  (it is the X-axis in the ROC curve). The area under the curve 
for each  is defined as . 
In Random Test, gene signatures are picked randomly and their performance is compared with 
the performance of our gene signature. Thus it acts as a measure of the significance of our 
signature when compared to some signatures picked randomly. 
2.4.2 COX Proportional Hazards model 
Cox Model was a regression model described by D.R.Cox in his paper, “Regression Models and 
Life-Tables” [18] in 1972. Since then till to date, Cox model is a well-recognized statistical 
technique which explores the relationship between survival times and several other predictors 
(also called covariates or explanatory variables) simultaneously [18]. In other words, it gives an 
estimate of the treatment effect on the survival after adjusting the covariates and also to estimate 
the risk of death. Cox model has many coefficients. For each variable these coefficients describe 
whether a patient is under poor prognosis or a good prognosis. 
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Cox model helps in isolating the effects of treatment from the effects of other variables or 
covariates. It helps in improving the treatment effect as it narrows down the confidence interval. 
Survival times are censored if the patients followed up for several years are still alive after the 
end of study. Their survival time is not known from their surgery, as it is even longer than the 
time in study.  
The regression model introduced by Cox is also known as proportional hazards regression 
analysis as it is used to explore several variables at a time. The hazard function is the probability 
that a patient will experience an event within a small interval of time, and therefore it can be 
understood as the risk of dying at time t. The hazard function denoted by h(t) can be estimated 
using the equation [19]. If two observations are considered as shown below, the hazard ratio of 
these two observations is shown in the last equation. 
          
     (2.22) 
 h t h t exp β . x  (2.23) 
 h t h t exp β . x  (2.24) 
 h t
h t
exp β . x
exp β . x  (2.25) 
2.4.3 Multivariate Analysis using COX Proportional Hazards model 
Regression is a statistical technique used to explain the relationship between the values of two or 
more variables. When more than one variable needs to be taken into account, the method is 
called multiple regression technique (multivariate analysis) which is almost the same as Cox’s 
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model except that Cox model allows considering in to account more than one explanatory 
variable at any one time. Thus hazard [19] at any time t can be expressed as  
 h t h t exp  β . age β . duration β . location  (2.26) 
By applying natural logarithms, we get 
 ln h t ln h t β . age β . duration β . location (2.27) 
Thus h t  is the underlying hazard function or baseline hazard. The coefficients such as 
β , β , … , β  are the regression coefficients and they constitute the proportional 
change that can be expected in the hazard or risk function related to the other variables which are 
estimated by a statistical method called the maximum likelihood technique. 
Consider two observations of hazards at times  i and  . 
 h t h t exp  β . age β . duration β . location  (2.28) 
 h t h t exp  β . age β . duration β . location  (2.29) 
The hazard ratio for the above two would be [19] 
 h t
h t
exp  β . age β . duration β . location
exp  β . age β . duration β . location  (2.30) 
Thus it can be seen that the hazard ratio does not depend on the baseline hazard. Proportional 
hazard is the assumption of a constant relationship between the dependent variable and the 
explanatory variables. Cox regression analysis will result in a final model which yields an 




The Kaplan-Meier curves, which are also known as product limit estimators, help in estimating 
the survival function from life time data. 
From a set of survival times, the proportion of the population who would survive a given length 
of time under the same circumstances can be estimated using the Kaplan-Meier [48] (or product 
limit) method. A plot of the Kaplan-Meier estimate of the survival function is a step function. 
The estimated survival probabilities are constant between adjacent death times and they only 
decrease at each death.  
If  is the number of samples at risk just prior to time  and  is the number of deaths at time 
, then Kaplan-Meier estimate would be the nonparametric maximum likelihood estimate of 
, which is the probability that a sample from the given population would have a lifetime 




Prognostic validation is usually done to predict the chance of recovery of a patient. Prognosis is 
normally estimated with the help of variables such as sensitivity, specificity, hazard ratios and 
log-rank p-values. Prognostic validation is done using the following methods 
1. Overall Accuracy 
2. Concordance Probability Estimate 




There are many metrics such as likelihood ratio, area under receiver operator characteristic 
(ROC) curve, overall accuracy, etc. which integrated both sensitivity and specificity to describe 
the validity of models or tests. Overall Accuracy is a single summary metric which is calculated 
from the 2  2 contingency tables which is the overall probability that a patient will be correctly 
classified by a model. A 2  2 contingency table is shown below. 
 
Accuracy =    =  (2.32)
   Accuracy = (Prevalence) (Sensitivity) + (1-Prevalence) (Specificity) (2.33)
Sensitivity is the probability that a person with the disease tests positive. Specificity is the 
probability that a disease-free person tests negative. Disease prevalence refers to the ratio of the 
number of patients with the disease and the total number of patients considered. Overall accuracy 
is the probability that a patient tests positive when he has the disease and tests negative when he 
is disease free; that is, the sum of true positives and the true negatives divided by the total 
number of patients. In other terms it can be shown to be the weighted average of the sensitivity 
and specificity where sensitivity is weighted by prevalence and specificity is weighted by the 
complement of prevalence. Thus the formulae for Sensitivity, Specificity and Overall Accuracy 
when a 2  2 contingency table is considered are shown above. 
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Overall accuracy as a measure has a limitation in the sense that it is prevalence dependent which 
sometimes gives a misrepresented idea of the validity of the model.  
2.5.2 Concordance Probability Estimate (CPE) 
Concordance probability is used to estimate the distinguishing power and the predictive accuracy 
of statistical models. CPE forms a stable estimator of predictive accuracy which can be 
computed easily. The proposed estimator for CPE is a function of regression parameters and the 
covariate distribution and is asymptotically unbiased. A concordance probability of 1.0 
represents a model that has perfect discriminating capacity where as a CPE of 0.5 indicates that 
the model is not good enough as it cannot discriminate between the observations in an accurate 
manner. If two observations ( , ) and ( , ) are considered, then their concordance 
probability [29] is defined as below. 
 , |  (2.34) 
If the value of CPE is less than 0.5, it does not mean that the model is bad, but it may be 
considered as below by taking –  instead of  as a predictor of  to obtain a CPE higher than 
0.5. 
 1 , | ,  (2.35) 
If    is a p-dimensional covariate vector, and  is the baseline hazard function independent 
of the covariates, and  is the vector of the regression parameters, then the hazard function 
|  of Cox proportional hazards model is given by 
 | exp  (2.36) 
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CPE is a simple function of the Cox proportional hazards model and is not sensitive to the degree 
of censoring and does not require imputation of survival times. 
The proportional hazards conditional survival function which determines the relationship 
between the p-dimensional covariate vector  and the survival time  is given by  
 ; , exp  (2.37) 
The ordering between the survival times of two subjects with log relative risks  and  
under proportional hazards can be measured by  
   ; , ; , 11  (2.38) 
Thus concordance probability |  may be written as 
 1
 (2.39) 
for integrals ranging over the interval  and  is the distribution function of the 
covariate linear combination . 








where  is the partial likelihood estimator for  and empirical distribution function was used for  
and  represents the pairwise difference . 
 
12.  http://www.broadinstitute.org/gsea/ 
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In R, a package for CPE exists which includes a command named “phcpe”. This command is a 
function used to calculate the Gonen & Heller concordance probability estimate (CPE) for the 
Cox proportional hazards model. It outputs the CPE and the standard error of the CPE. The input 
for phcpe is a Cox fit model. Since a Cox fit model is present, we get various outputs such as p-
values from log-rank tests, hazard ratios and the confidence intervals also as outputs from phcpe. 
The CPE values must always be greater than 0.5 for a data to be significant. The higher the CPE 
values, the more significant the data is considered to be. Similarly, p-values from log-rank tests 
must be lesser than 0.05 and hazard ratios must be greater than at least 1. 
2.5.3 Gene Set Enrichment Analysis (GSEA) 
Gene Set Enrichment Analysis12 is a powerful analytical method that computes whether a 
predefined set of genes is statistically significant and whether the gene set has agreeable 
differences between the two phenotypes (biological states). GSEA interprets gene expression 
data and focuses on the gene sets as a whole. It generates analysis based on the groups of genes 
that share common biological function, chromosome location or regulation. 
GSEA [30] works in three steps: 
1. Calculation of an Enrichment Score (ES): ES is the maximum deviation from zero 
encountered in a random walk which corresponds to the Kolmogorov-Smirnov-like statistic. 
It is calculated to show whether the gene set is overrepresented at the top or bottom of the 
ranked list. 
2. Estimation of the significance level of ES: The nominal P value of the enrichment score 
which denotes its statistical significance is estimated by using an empirical phenotype-based 
permutation test. The permutation of phenotypes preserves the complex correlation structure 
 
13.  http://crfb.univ-mrs.fr/webdistin/ 
14.  http://www.genome.jp/kegg/ 
15.  http://pid.nci.nih.gov/ 
16.  http://www.ncbi.nlm.nih.gov/pubmed/ 
17.  http://acgt.cs.tau.ac.il/matisse/ 
18.  http://string.embl.de/ 
19.  http://www.ingenuity.com/ 
20.  http://www.ariadnegenomics.com/products/pathway-studio/ 
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of the gene expression data which provides a more biologically reasonable estimation of 
significance. 
3. Adjustment for Multiple Hypothesis Testing: After the complete database of gene sets is 
assessed, the estimated significance level is adjusted to account for multiple hypothesis 
testing by calculating the normalized enrichment score (NES) and the false discovery rate 
(FDR). FDR is the estimated probability that a gene set with a given NES represents a false 
positive finding. 
2.6 Topological Validation 
Structural validation is done using the following methods 
1. PRODISTIN13 
2. PubMed14 
3. NCI Pathways15 
4. KEGG16 
5. MATISSE17 
6. STRING 818 
7. Ingenuity Pathway Analysis19 
8. Pathway Studio20  
2.6.1 PRODISTIN 
PRODISTIN method functionally classifies genes or proteins from all types of interaction 
networks according to the identity of their interacting partners. It can also be used to obtain 
information related to protein function and to relationships linking cellular processes [22]. 
Proteins can be compared functionally at the cellular level or the molecular level. In 
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PRODISTIN method, proteins are clustered according to their cellular processes more efficiently 
rather than the molecular or the biochemical functions. The result of PRODISTIN method on 
interaction networks allows the user to acquire a classification tree in which network 
genes/proteins are grouped according to their functional similarity and to find out functional 
classes in the tree using the biological process Gene Ontology annotations of genes/proteins. The 
basic concept is that the more two proteins share interacting partners, the more they should be 
functionally related.  
PRODISTIN method consists of two different and successive bioinformatic steps as shown in 
Figure 2-15 below. Initially a graph including all proteins connected by a specific relation is 
constructed and Czekanowski-Dice distance is calculated between all possible pairs of proteins 
in the graph with respect to the interacting partners they share. This classical distance on graphs 




# #  (2.41) 
where i and j denote two proteins, Int(i) and Int(j) are the lists of their interacting partners plus 
themselves (which are used to decrease the distance between the proteins interacting with each 
other) and ∆ is the symmetrical difference between the two sets. In other words it gives sum of 
the interactors in both minus twice the number of common interactors between the two 
interacting proteins. This distance was chosen because it increases the weight of the shared 
interactors by giving more importance to the similarities than to the differences and also it 
authorizes the use of tree representation. For two proteins that do not share any interactors, the 
distance is 1 and is the maximum value. For two proteins interacting with each other and sharing 
exactly the same interactors, the distance is 0 and is the minimum value. The second step would 
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be to cluster all the distance values according to BioNJ, which would lead to a classification tree. 
The tree can be visualized and subdivided in to formal classes according to the biological process 
in Gene Ontology annotations. 
 
Figure 2-15: Step wise procedure for PRODISTIN method [21] 
 
PRODISTIN has the ability to predict correctly, the function for unknown proteins and it shows 
reliability even in the presence of both spurious and missing interactions in the dataset. It can 
also be used to investigate the evolution of the function of duplicated genes. As more interactions 
become available, it improves the relevance of the protein clusters found by the PRODISTIN 





Figure 2-16: PRODISTIN website 
 
2.6.2 PubMed 
PubMed was developed by National Centre for Biotechnology Information (NCBI) at National 
Library of Medicine (NLM) located at U.S. National Institutes of Health (NIH). It is available 
through Entrez retrieval system. It helps search in biomedical citations and abstracts. PubMed is 
a search engine that allows access to many databases including the MEDLINE database of 
journal articles. Its focus is on medicine and related fields like nursing.  
PubMed can be searched for required details in many ways as shown below in Figure 2-17. Any 
data required can be searched in entire PubMed or it can be restricted to some fields such as 
genes, proteins, journals, etc. The results could be even more focused by choosing the limits of 
search such as the organisms, taxonomy, etc. It is one of the web based search engines which is 
used widely by biostatisticians to extract gene information. 
Advanced search is also available which allows finding data by author’s name, publication date, 
title, etc. as shown below in Figure 2-18. The recent items searched are also stored and they can 
be revisited when required. PubMed has an option called LinkOut which allows to access 
resources in external websites directly from the PubMed database. LinkOut resources include 
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research tools, full text publications, biological databases, etc. Thus instead of searching various 
databases each separately, it would be sufficient to check in PubMed which give links to all the 
other databases if they are present. The links are present in such a way that we could access just 
the abstract or the entire text in required format (text or pdf). 
 
Figure 2-17: PubMed website 
 
 





National Cancer Institute (NCI) is a part of the U.S. National Institutes of Health and supports a 
national network of cancer centers and supports research projects in cancer control. Nature 
Publishing Group (NPG) is a publisher of 60 prestigious scientific journals including the highly 
impact Nature, the international weekly journal of science. A collaborative project between NCI 
and NCI is the Pathway Interaction Database (PID).  
PID is a highly structured database which includes a curated collection of information. The 
schema of the database is very flexible which makes it easy to store a wide range of information 
about cell signaling pathways. It includes known biomolecular interactions that are taking place 
in human cells and also includes key cellular processes which when combined make up signaling 
pathways. PID shows not only the predefined pathways but also interaction networks that are 
dynamically constructed. Since the editorial section of PID also includes outlines of recent 





Figure 2-19: Pathway Interaction Database 
 
 




PID includes many pathways extracted from three types of data as shown in Figure 2-19 and 
Figure 2-20. They are NCI-Nature Curated data, BioCarta data and Reactome data. NCI-Nature 
Curated data are produced by Nature Publishing Group according to a few principles. They 
include Human Model System, Biological relevance, Authority and Consistent nomenclature. 
BioCarta was imported in to PID in June 2004 and Reactome was imported in December 2007. 
In NCI-Nature Curated data and Reactome data, biomolecules are annotated with Uniprot protein 
identifiers and relevant post-translational modifications whereas in BioCarta data, biomolecules 
are annotated by Entrez gene identifiers without post-translational modifications. 
A biologically meaningful set of interactions is defined as a pathway in PID. Molecular 
interaction is the basic unit of representation in PID. Thus the information is very fine-grained 
and highly structured. In each interaction, each biomolecule is identified along with the nature of 
process (biological events) it is involved and its role in each of the processes. Pathways are 
portrayed graphically labeled nodes and edges. Additional references are also provided. 
2.6.4 KEGG 
KEGG stands for Kyoto Encyclopedia of Genes and Genomes. It was initiated in May 1995 to 
computerize the knowledge of molecular and cellular biology in terms of information pathways 
that consist of interacting genes or molecules. Its objective was to link [24] the structural data 
obtained by genome projects and the functional data. KEGG was built based on the pair wise 
interaction of genes or molecules. Since information regarding known pathways has been 
expanding rapidly, it has become necessary to computerize known pathways at the time of 
KEGG’s initiation. KEGG was considered to be an effort to advance concepts and technologies 
and real time data collection efforts [26]. KEGG contains an aspect of the deductive database 
where new interactions could be deduced from relations stored in database. Thus the basic 
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concept of KEGG is the relation and deduction. KEGG has a hierarchy which is important in the 
sense that it represents functional, structural and evolutionary relationships of genes and 
molecules. The advancements in the database and networking technology make KEGG even 
better in the aspect of its functionality especially the deductive and object-oriented databases. 
KEGG consisted of three databases [23, 25] when it started. KEGG PATHWAY represents 
higher order functions in terms of the network of interacting molecules (mostly proteins). It is a 
set of manually drawn pathway maps which represent knowledge on the molecular interaction 
and reaction networks and also on structural relationships. The best organized part of 
PATHWAY is that the organism specific pathways are constructed computationally by 
correlating genes in the genome with gene products in the reference pathways according to the 
matching EC numbers. Gene catalogs for all the completely sequenced genomes and some partial 
genomes are accumulated under KEGG GENES. The number of GENES’s entries keeps 
increasing every year to keep track of the updating genome sequences. Thus GENES acts as a 
gateway to a number of other resources containing more detailed information. KEGG LIGAND 
is the collection of chemical compounds in the cell, enzyme molecules and enzymatic reactions. 
It is a composite database which includes COMPOUND, DRUG, GLYCAN, REACTION, 






Figure 2-21: KEGG Website 
 
 





KEGG was later updated with many other databases which came up to 19 databases categorized 
in to systems information, genomic information and chemical information. KEGG website can 
be seen in Figure 2-21 and KEGG PATHWAY is shown in Figure 2-22 above. 
2.6.5 MATISSE 
MATISSE is a program that implements a novel computational method for efficient detection 
and analysis of JACSs. JACSs are Jointly Active Connected Subnetworks which are the 
functional modules that are sought by identifying the connected subnetworks in the interaction 
data that exhibit high average internal similarity [27]. MATISSE has a statistical basis, which 
allows confidence estimation of the results and no prior knowledge of the JACSs is required 
which removes the requirement of precalculation of the statistical significance of expression 
values. Thus it suits all types of network data overlaid with pair wise similarities. 
 
Figure 2-23: MATISSE interface 
 
 





Figure 2-25: Displaying the module 
 
MATISSE needs to choose a species first and then the interaction network and the expression 
data must be loaded as shown in Figure 2-23. After the data is loaded, modules must be found 
and for that the Algorithm which must be used to find the modules must be selected as shown in 
Figure 2-24. The displayed modules can be filtered by applying filters which is shown in the 
Figure 2-25. 
MATISSE detects non-overlapping JACSs by identifying heavy subgraphs in an edge-weighted 
similarity graph while maintaining connectivity in the interaction network. There are three 
phases in the detection and analysis of JACSs: (1) relatively small, high-scoring gene sets, called 
seeds must be detected; this detection can be done by any of the methods such as Best-neighbors 
or All-neighbors or Heaviest-subnet, (2) Seed improvement or greedy optimization; this 
optimization can be done using the methods like Node addition, Node removal, Assignment 
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change, and JACS merge, (3) significance-based filtering; the empirical p-value of the score was 
calculated for each JACS and a threshold of p=0.05 is applied. 
 
Figure 2-26: Module from MATISSE 
 
 
Figure 2-27: Module from Co-clustering method 
In MATISSE, modules are also generated using Co-clustering method for the purpose of 
comparison. Co-clustering methodology uses a distance function that combines similarity of 
gene expression profiles with network topology. A few properties include Expression 
homogeneity (calculated as the Pearson correlation between genes within the same module), 
edge density (number of edges it contains as a fraction of all its node pairs), and clustering 
coefficient (fraction of a node’s neighbor pairs connected in the network). MATISSE is designed 
to produce connected subnetworks as shown in Figure 2-26 whereas Co-clustering generates 
modules that are highly disconnected as shown in Figure 2-27 above. Thus MATISSE is much 
better [27] in all the properties checked for comparison with Co-clustering technique.  
2.6.6 STRING 8 
STRING 8 stands for eighth version of Search Tool for the Retrieval of Interacting 
Genes/Proteins. It is a database and web resource that constitutes most of the available protein-




also with the results of automatic literature-mining searches. The latest version of STRING 8 
covers almost 2.5 million proteins from 630 organisms and thus it provides a very 
comprehensive view of the protein-protein interactions. It includes resources from various other 
sources such as MINT, HPRD, BIND, DIP, BioGRID, KEGG, Reactome, IntAct, EcoCyc, NCI-
Nature Pathway Interaction Database, and Gene Ontology (GO) protein complexes, etc. Apart 
from the interactions previously known interactions from the above resources, STRING 8 uses a 
number of prediction algorithms that computationally predict many more interactions. It searches 
for genes that are found in close surroundings of chromosomes as it would be a good indication 
of functional relation. It then searches for instances where genes join to encode a single fusion 
protein. It also searches for gene families that have similar phylogentic profiles and also genes 
that are co-expressed under different conditions. It includes interactions identified from text 
mining of databases like SGD, OMIM, The Interactive Fly and all the abstracts of PubMed. 
STRING 8 is more fault tolerant when clustering conserved neighborhoods by ignoring false 
predictions.  
The network images in STRING are generated using a spring model where nodes are taken as 
masses and the edges are considered as springs.  
In STRING 8, one or more proteins of interest are entered as inputs by giving names or 
identifiers as shown in Figure 2-28. The appropriate organism is selected. STRING 8 also has a 
random input generator which will select randomly a gene/protein with a minimum of 4 
predicted links above medium confidence or even better. Prediction summary is obtained for the 




of them can be viewed in detail. The various types of evidence supporting the predicted 
associations can be viewed by clicking the different views of the data. 
 
Figure 2-28: STRING 8 web interface 
 
The network view briefly summarizes the interactions between the proteins with each of the 
protein as a node in the network. Any two proteins may be connected using seven different 
colored functional associations where each color indicates the presence of one evidence. A red 
line implies presence of fusion (individual gene fusion events per species) evidence; a green line 
implies conserved neighborhood (genes that occur repeatedly in close neighborhood in genomes) 
evidence; a blue line implies co-occurrence (presence or absence of linked proteins across 
various species) evidence; a purple line implies experimental (list of significant protein 
interaction datasets acquired from other protein-protein databases) evidence; a yellow line 
implies text mining (list of significant protein interaction groups extracted from the literature) 




from curated databases) evidence; a black line implies co-expression (genes that are co-
expressed in the same species or other species) evidence. Clicking on a node gives many details 
about the protein and clicking the edge gives all the different scores relating to each of the 
evidences. 
2.6.7 Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA) integrates data from a variety of experimental platforms. It 
provides insight into molecular and chemical interactions, cellular phenotypes, and disease 
processes of our system. IPA is built upon a huge foundation of scientific evidence which 
include journal articles, textbooks, and other data sources. It presents the data in a meaningful 
visual and knowledgeable way.  
There are different types of analyses that can be performed on a group of genes. They include 
Core analysis, IPA-Tox analysis, IPA-Metabolomics or IPA-Biomarker analysis. These analyses 
in most cases give a good indication of what cellular processes the given dataset is related to. 
Core analysis is used to interpret datasets in the context of biological processes, pathways and 
molecular networks. IPA-Metabolomics analysis analyzes the metabolite data about cell 
physiology and metabolism. IPA-Tox analysis assesses the toxicity and safety of the compounds 
of interest. It also shows the appropriate toxicity phenotypes and clinical pathology endpoints 
related to a dataset. IPA-Biomarker analysis identifies and prioritizes the most appropriate and 
promising molecular biomarker candidates from the datasets. Each of these analyses can be run 
multiple times on different inputs and they can be compared among themselves using 





Ingenuity systems have a database that is highly structured and context-rich which makes it 
unique among the different pathway applications. All the results found in IPA are always 
supported by experimental results and thus are not just based on the occurrence in few abstracts. 
These results are structured in to an ontology which lets the use of very powerful computational 
algorithms that presents the results in IPA when queried.  
IPA includes many features such as integrated broadband coverage of systems biology (including 
protein, gene, protein complex, cell, cellular component, tissue, organ, small molecule, and 
disease interrelationships), broad genome wide coverage of human, mouse, and rat genes, huge 
number of pathway interactions extracted from literature, very systematic capture of canonical 
pathway relationships and almost up to date literature. 
IPA uses different shapes for the nodes in the networks and different types of connectors 







Figure 2-29: Different Network and Path Designer shapes along with Relationships used in IPA to represent 
different types of data 
 
It is not an open source and hence a license is needed to use the entire version of IPA. There is a 
free trial version but it does not include all the pathways and hence same results are not obtained 
each time it is used. 
2.6.8 Pathway Studio 
Pathway Studio is a combination of three products: 
1. ResNet database 
2. MedScan application 
3. Pathway Studio interface 
ResNet is a database that comprises of the biological relations, ontologies and pathways that 




research. This database stores information that has been successfully extracted from PubMed in a 
manner such it allows searching, retrieving and even updating of the database by the user. 
Moreover the extracted interactions have access linked to the original data source. All possible 
aliases are also included which excludes redundancy and thus maintains identity of the genes. 
MedScan is a computational approach used for data analysis that has the information from 
literature as a coherent and integrated part within it. It is like a web search engine which not only 
gathers knowledge about a query but also scans the literature for relationships and highlights 
those relationships in the articles that were gathered. It also lists all the relationships and 
molecular processes in appropriate tables which can be saved in to the ResNet database and 
reused for further analysis. MedScan has access to PubMed and 47 full-text journals and 
additional journals may also be added from different sources. MedScan can thus create many 
databases of specific organisms, diseases, etc and it can highlight different proteins, chemicals, 
cell processes, etc in literature. MedScan is used to update ResNet database and this can also be 
automated. 
Pathway Studio is a software which analyses gene expressions and builds pathways. These 
pathways can be expanded and various relationships between genes, proteins, diseases, etc can 
be extracted. It works together with ResNet database (and MedScan reader to update the 
database). Once the experimental data is imported in to Pathway Studio, it enables in-depth 
analysis of the data and relationships are extracted from the literature (PubMed). By changing 
the settings in Pathway Studio, it can find common regulators and relates pathway components 





Figure 2-30: Different shapes and colors used in Pathway Studio to represent for different types of data 
 
There are 227 receptor signaling and 21 new cellular process regulation pathways that are 
included in Pathway Studio. These can be further expanded using MedScan. Pathway Studio is 
not an open source and license is needed to use it. 
2.7 Summary 
This chapter discussed the advantages of network-based techniques over feature selection 
methods. Feature selection procedures considered the behavior of each gene individually. Hence 
this chapter highlighted the importance of considering the “gene interactions” instead of each 
gene individually. It also reviewed the various network-based techniques such as correlation-
based and clustering-based coexpression networks, Bayesian networks and artificial neural 




network-based techniques have been discussed. The correlation-based coexpression networks 
and the clustering based coexpression networks do not provide predictive structure or causal 
relations. Moreover their accuracy decreases with increase in network size. Bayesian networks 
cannot contain loops and they require subjective priors. Neural networks are time consuming and 
have the possibility of overtraining. It was thus discussed that all these limitations have been 
overcome by the implication networks. Algorithm of the implication network that was used in 
identifying the gene signatures was explained. Different validation techniques and tools, used for 
both prognostic and topological validation of the signature identified from the implication 









In the earlier chapter, major limitations of the compared network techniques along with the 
advantages of implication networks were emphasized. In this chapter, details will be focused on 
how implication networks were applied on the dataset and how gene signatures were identified. 
Moreover descriptions of the datasets, procedures and results obtained from the application of 
implication networks are provided.  
 





The flow chart of the methodology is shown in the Figure 3-1 above. The first top box of the 
flow chart as displayed constitutes the identification of the gene signatures and this part will be 
discussed in this chapter. Details of survival analysis will also be given in this chapter. 
3.2. Methodology for identifying prognostic gene signatures 
Identification of the gene signature is done on the training dataset and the validation of the 
obtained signature is performed on the test datasets. 
The gene expression data of the training dataset is divided in to two or more groups based on 
some variables such as survival time, survival status, smoking status, etc. In this thesis, survival 
time and survival status are used together to split the data in to two groups. These groups are 
named Metastasis group (high risk group) and Non-Metastasis group (low risk group). 
Interactions among the genes are induced using prediction logic algorithm [1, 2]. Thus genome 
wide networks for both the groups are generated. After we get interactions among the genes in 
both the groups (Metastasis and Non-Metastasis), differential components between the groups 
are picked. Differential components are the set of interactions that are present in one group but 
are not present in the other group and vice versa. In other words, differential components of 
Metastasis group are unique and similarly, differential components of Non-Metastasis group are 
unique. Thus we get the interactions that differentiate the high risk group and the low risk 
groups. 
Once the differential components are found, all the genes interacting with the major cancer 
hallmarks are picked. Major cancer hallmarks are genes that were already known to be of great 
importance in cancer research. Since these genes are known to have strong interactions with 




genes, might be in one or the other manner, included in the regulation or progression of tumors. 
Hence the set of genes that interact with all the major cancer hallmarks are considered to form a 
signature. By varying the set of hallmarks, we get different signatures. 
Once signatures are found, we validate these signatures to find a signature that outperforms the 
other signatures and later evaluate the better signature prognostically and topologically (this will 
be dealt in the next chapter). 
3.2.1 Datasets Information 
The data required for acquiring, training and testing the signatures was taken from a consortium 
[20] which was formed with the support and collaboration of US National Cancer Institute 
investigators. The dataset is a combination of samples collected from four institutions [20] using 
a common platform. The institutions that formed the consortium include University of Michigan 
Cancer Center (UM), Moffitt Cancer Center (HLM), Memorial Sloan-Kettering Cancer Center 
(MSK) and the Dana-Farber Cancer Institute (CAN/DF). The data from UM had 177 samples, 
HLM had 79 samples, CAN/DF had 82 samples and MSK had 104 samples. There were a total 
of 442 samples and 22215 genes. The data from UM and HLM were combined to form the 
Training dataset which has 256 samples. This Training dataset was used to find signatures and 
then they were validated on the remaining two datasets (CAN/DF and MSK). 
3.2.2 Dataset processing 
The Training dataset consists of 22215 genes and 256 samples. There were duplicate probes for 
many genes. The duplicate probes of every single gene were averaged. This narrowed down the 
number to be 13658 unique genes. This data was split in to 2 files, Metastasis (High risk) and 




their survival status. If the number of months the patients survived was greater than 60 (5 years), 
the sample was put in Non-Metastasis group (Low risk). If the number of months the patients 
survived was less than 60 months and if it was known that the patient died, the sample was put in 
Metastasis group (High risk). If the number of months the patients survived was less than 60 
months and if it was not known whether the patient died, the sample was censored. The 
Metastasis group (High risk) consisted of 125 patients and the Non-Metastasis group (Low risk) 
consisted of 104 patients. There were 27 samples that did not fall in to either of the groups and 
hence they were censored. Then the data values were converted in to binary values (0’s and 1’s) 
based on the mean of the expression values of each gene. The mean values were calculated using 
bootstrapping so that the impact of the number of samples being different does not affect the 
value of the mean. If the expression value of each gene for each sample was less than or equal to 
the mean of all samples for that particular gene, it was defined as 0 and if it was greater it was 
defined as 1. 
3.2.3 Deriving genome scale gene interactions 
The interactions between the 13658 genes in each of the groups containing 125 (for metastasis 
group) and 104 (for non-metastasis group) samples were derived. The underlying principle in 
generating the gene interactions is based on prediction logic used for inducing the implication 
network [1, 2]. The minimum scope and minimum precision required were calculated using 
simple Z-test for a cutoff value of 1.64. There were 159,402,305 interactions that were derived 
from the Metastasis group (High risk). There were 154,144,728 interactions that were derived 
from the Non-Metastasis group (Low risk). The comparison of the number of interactions from 





After the genome wide interactions for the dataset were obtained, the differential components of 
each of the groups were obtained. Differential components are the gene interactions of one group 
that are not present in the other group. The interactions present in Metastasis group (High risk) 
but not present in the Non-Metastasis group (Low risk) are called the differential components of 
Metastasis group (High risk). Similarly, the interactions present in the Non-Metastasis group 
(Low risk) but not present in the Metastasis group (High risk) constitute the differential 
components of the Non-Metastasis group (Low risk). In other words they are the interactions that 
differentiate the two groups from one another. There were 91,445,437 common interactions 
between the groups. Thus there were 67,956,868 differential components for Metastasis group 
(High risk) and there were 62,699,291 differential components for Non-Metastasis group (Low 
risk) were. The comparison of the differential components from both the groups along with the 
genome wide interactions is shown below in Figure 3-2. 
 
Figure 3-2: Bar graph showing the number of interactions in Poor (high risk) and Good (low risk) prognosis 






Major Cancer Hallmarks are the genes which are considered to be important. A different set of 
hallmarks can be considered to find different signatures. Gene signatures are picked from the 
genes which have interactions with all the hallmarks. There were 7 hallmarks that were 
considered to find gene signatures. Six of them were EGF, EGFR, KRAS, MET, RB1, and TP53. 
The seventh hallmark E2F had five different probes E2F1, E2F2, E2F3, E2F4, and E2F5. Hence 
they totaled to 11 hallmarks. 
3.2.6 Identifying Gene Signatures  
All the genes which had interactions with the entire set of 11 hallmarks were picked from both 
the Metastasis group (High risk) and the Non-Metastasis group (Low risk). There were 7 genes 
from the Metastasis group (High risk) and 4 genes from the Non-Metastasis group (Low risk) 
which totaled up to an 11 gene signature. 
E2F had multiple probes and thus their functional properties were considered. A few subsets of 
the 11 hallmarks with the help of PubMed were considered to identify gene signatures.  
E2F1, E2F2, and E2F3 were a family with functional similarities and E2F3 had the least 
significance among them. So it was ignored. Similarly E2F4 and E2F5 were another family with 
functional similarities and E2F5 is not as significant as E2F4. So it was ignored.  
Thus E2F1, E2F2, and E2F4 were only included with the. remaining 6 hallmarks to make a set of 
9 hallmarks to find another signature. The genes that had interactions with all the 9 hallmarks 
were picked from both the Metastasis group (High risk) and the Non-Metastasis group (Low 
risk). There were 13 genes from the Metastasis group (High risk) and 8 genes from the Non-




Since E2F1 and E2F2 were a part of the same family, they had similar functionality and so they 
were considered one at a time to find more gene signatures. 
When E2F1 and E2F4 were considered along with the remaining 6 hallmarks, there were a total 
of 8 hallmarks. All the genes that had interactions with the 8 hallmarks were picked from both 
the Metastasis group (High risk) and the Non-Metastasis group (Low risk). There were 18 genes 
from the Metastasis group (High risk) and 13 genes from the Non-Metastasis group (Low risk) 
which totaled to a 31 gene signature. 
When E2F2 and E2F4 were considered along with the remaining 6 hallmarks, there were a total 
of 8 hallmarks. All the genes that had interactions with the 8 hallmarks were picked from both 
the Metastasis group (High risk) and the Non-Metastasis group (Low risk). There were 32 genes 
from the Metastasis group (High risk) and 19 genes from the Non-Metastasis group (Low risk) 
which totaled to a 51 gene signature. But there was one gene which was common to both the 
groups and thus the signature size becomes 50. 
The number of genes identified from each group using different sets of hallmarks is shown in the 
Table 3-1 below. 
Table 3-1: Number of genes identified to have interactions with major cancer hallmarks in each prognosis 










Hence 4 signatures were discovered where each one had 11 genes, 21 genes, 31 genes, and 50 
genes which are shown in Table 3-2 below. The 50 gene signature has a gene FLJ13059 that was 
extracted from both groups. 
It can be seen that the 11 gene signature is a subset of all the remaining 3 signatures (21 gene, 31 
gene, and 50 gene signatures) and the 21 gene signature is a subset of the remaining 2 signatures 
(31 gene and 50 gene signatures). This was because the set of hallmarks used for identifying the 
31 gene signature and the 50 gene signature were subsets of the hallmarks used for identifying 
the other 2 signatures (11 gene and 21 gene signatures). 
But the 31 gene signature and the 50 gene signature had a few unique genes each. Other than the 





Table 3-2: All signatures obtained using different combinations of Hallmarks 
   50‐GENE SIGNATURE  31‐GENE SIGNATURE  21‐GENE SIGNATURE  11‐GENE SIGNATURE 
1  ACTL6B  ACTL6B  ACTL6B  ACTL6B 
2  ADAM3B  ADAM3B  ADAM3B  ADAM3B 
3  FABP7  FABP7  FABP7  FABP7 
4  PRR4  PRR4  PRR4  PRR4 
5  RPL27A  RPL27A  RPL27A  RPL27A 
6  SLC22A11  SLC22A11  SLC22A11  SLC22A11 
7  TAC3  TAC3  TAC3  TAC3 
8  215642_at  215642_at  215642_at  215642_at 
9  DEFA5  DEFA5  DEFA5  DEFA5 
10  PALM  PALM  PALM  PALM 
11  SCGB2A2  SCGB2A2  SCGB2A2  SCGB2A2 
12  BCDIN3  BCDIN3  BCDIN3    
13  GAL3ST1  GAL3ST1  GAL3ST1    
14  PCDHB3  PCDHB3  PCDHB3    
15  PCDHGA3  PCDHGA3  PCDHGA3    
16  PRKACA  PRKACA  PRKACA    
17  SAMD4B  SAMD4B  SAMD4B    
18  ACTR8  ACTR8  ACTR8   
19  CAP2  CAP2  CAP2   
20  CDKN2B  CDKN2B  CDKN2B   
21  TMEM135  TMEM135  TMEM135   
22  217363_x_at  C1orf68         
23  BRD2  dJ222E13.2       
24  C9  LOR       
25  COG5  SSFA2       
26  DDB1  TEX11       
27  DKFZP586P0123  217470_at       
28  ESM1  DAG1       
29  FLJ13059  ESM1       
30  GABRA1  H2AFB3       
31  HSPA2  TM4SF20         
32  KRT81            
33  MUC8            
34  PEX5L            
35  PPP1R2P9            
36  PRKAA1            
37  SUPT6H            
38  TPSD1            
39  TRIM9            
40  VPS35          
41  ATP6V0B         
42  CHD6         
43  DUSP21         
44  ELL         
45  KIAA1446         
46  SCN8A            
47  SLC26A1            
48  SPINK5            
49  STT3A            





To find the most significant signature from the obtained prognostic signatures, survival analysis 
was performed on the four signatures. Survival Analysis was done using techniques which 
include Time dependant ROC analysis, Random Test, and Cox proportional hazard model. Cox 
model uses Kaplan-Meier plots and log-rank tests to identify the best signature. 
3.3.1 Time dependant ROC analysis and Random Test 
ROC curve stands for Receiver Operating Characteristic curve. It is a plot between the sensitivity 
and the (1-specificity) as time is varied. It can also be considered as the plot between the True 
Positive Rate and the False Positive Rate. That is it is used to describe the tradeoff between the 
hit rates and the false alarm rates. The higher the area under curve (AUC) values, the better the 
signature. The AUCs are calculated using R. 
In Random test, genes are picked randomly from the entire set of genes. The number of genes 
picked must equal the number of genes in the signature that is being validated. The AUC of the 
signature genes is compared with the AUC of the picked genes. Similarly, a large number of 
randomly picked signatures are compared with the signature that is being validated. The 
performance of the identified gene signature must be significant when compared to the other 
randomly picked signatures. The lower the p-value from the random test is, the better is the 
signature. 
In the datasets, when there were duplicate probes for genes, the probe that resulted in the most 
significant (least) p-value when fitted in to Cox model was considered the best probe and was 
used for time dependant ROC analysis of the entire signature. Thus time dependant ROC 




and MSK). The function “coxph” in R was used for the calculation of p-values to find the most 
significant probe from duplicate probes. 
The Tables 3-3, 3-5, 3-7 show the AUC values over years starting from 1 to 9 and for all the four 
identified signatures in training dataset, DFCI test set and MSK test set respectively. The Tables 
3-4, 3-6, 3-8 are the p-values of the corresponding signature obtained when compared to the 
randomly picked signatures from random test for training dataset, DFCI test set and MSK test set 
respectively. 
Table 3-3: AUC’s of training set (256 samples) obtained when best probes among duplicates were considered 
  11-gene 21-gene 31-gene 50-gene 
1-year 0.684292 0.73329 0.777634 0.812282 
2-years 0.648464 0.683333 0.729109 0.722581 
3-years 0.661654 0.684145 0.711605 0.730173 
4-years 0.642624 0.675829 0.704544 0.715059 
5-years 0.640428 0.687573 0.707053 0.728794 
6-years 0.64902 0.69424 0.703125 0.749081 
7-years 0.644137 0.696312 0.711665 0.749984 
8-years 0.628796 0.68712 0.699266 0.743927 
9-years 0.618716 0.680933 0.693261 0.744874 
 
Table 3-4: p-values from Random test of training set (256 samples) obtained when best probes among 
duplicates were considered 
  11-gene 21-gene 31-gene 50-gene 
3yr random 0.05 0.11 0.12 0.35 
5yr random 0.32 0.26 0.38 0.78 
 
As per the values shown in the Tables 3-3 above for Training dataset, ROC values were good for 
the 50 gene dataset. But according to Table 3-4, the Random test values were bad. The Random 




tradeoff between the AUC values and the Random Test values points to the 31 gene signature 
which is nearly good in both the validations. 
Table 3-5: AUC’s of DFCI test set (82 samples) obtained when best probes among duplicates were considered 
 11-gene 21-gene 31-gene 50-gene 
1-year 0.610755 0.682458 0.773368   
2-years 0.660634 0.716742 0.80724   
3-years 0.712601 0.778187 0.847458 Error in fitter  
4-years 0.706731 0.802885 0.866071 Ran out of iterations 
5-years 0.719577 0.789021 0.831349 and did not converge 
6-years 0.7225 0.780625 0.839375  
7-years 0.731618 0.77451 0.834559    
8-years 0.728875 0.774468 0.828571   
9-years 0.728875 0.774468 0.828571   
 
Table 3-6: p-values from Random test of DFCI test set (82 samples) obtained when best probe among 
duplicates were considered 
 11-gene 21-gene 31-gene 50-gene 
3 yr random 0.51 0.45 0.61 Error in fitter  
5yr random 0.49 0.67 0.7 Ran out of iterations 
From the Table 3-5 above for DFCI dataset, it was seen that the 50 gene signature had errors to 
fit in the model and hence was be ruled out. Since the Random test values from Table 3-6 were 
not good for any signature in this dataset, only the AUC values were considered to decide that 
the 31 gene signature was better than the other signatures. 
Table 3-7: AUC’s of MSK test set (104 samples) obtained when best probes among duplicates were 
considered 
 11-gene 21-gene 31-gene 50-gene 
1-year 0.778878 0.933993 0.980198  
2-years 0.720284 0.78876 0.861757  
3-years 0.764359 0.828234 0.880837 Error in fitter  
4-years 0.742069 0.816092 0.848736 Ran out of iterations 
5-years 0.72479 0.833613 0.85 and did not converge 
6-years 0.740196 0.841503 0.851307   




8-years 0.745865 0.842275 0.84994   
9-years 0.745865 0.842275 0.84994   
 
Table 3-8: p-values from Random test of MSK test set (104 samples) obtained when best probes among 
duplicates were considered 
 11-gene 21-gene 31-gene 50-gene 
3yr random 0.23 0.19 0.23 Error in fitter  
5yr random 0.35 0.08 0.32 Ran out of iterations 
From the values from the Table 3-7 above for MSK dataset, it was seen that the AUC values 
show in favor of the 31 gene signature where as the Random test values from Table 3-8 were in 
favor of the 21 gene signature. 
Thus considering all the three datasets, Time dependant ROC values and Random test together 
were more in favor of the 31 gene signature over the other signatures. 
3.3.2 Cox proportional hazards model on 11, 21 and 31 Gene Signatures 
For the COX modeling, the training dataset is first fit in to the Cox model and then the cutoff 
values obtained by the fitting are applied on the test datasets. Three different cutoffs from 
training dataset were used which are mean, median and the nearest point. 
Mean or Median as cutoff: 
The means/medians of the samples of the training dataset were calculated and were applied as 
the cutoffs for the test datasets. Kaplan Meier plots were plotted to see if the stratification was 
significant. Only three signatures (11-genes, 21-genes and 31-genes) were considered for 
evaluation in Cox model. The fourth signature was ignored as it gave errors in the previous 
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cutoff point from training set was used to fit the test datasets in the Cox model.Kaplan Meier 
plots of the outputs were drawn as shown in Figure 3-5 and Figure 3-6. 
 
Figure 3-5: KM plot of DFCI data with nearest 
point cutoff of training data for 31 gene signature 
 
 
Figure 3-6: KM plot of MSK data with nearest 
point cutoff of training data for 31 gene signature 
 
Table 3-9: Cox model outputs for various cutoffs of training dataset applied on both DFCI and MSK test 
datasets for 11-gene signature 













































From the Table 3-9 above, it can be seen that the log-rank p-values for 11 gene signature for 
MSK dataset were significant but they were not significant for the DFCI dataset for any kind of 
cutoff values. 
Table 3-10: Cox model outputs for various cutoffs of training dataset applied on both DFCI and MSK test 
datasets for 21-gene signature 









































From the Table 3-10 above, it can be seen that the log-rank p-values for 21 gene signature were 
significant, except when the mean was used as a cutoff for DFCI dataset. 
Table 3-11: Cox model outputs for various cutoffs of training dataset applied on both DFCI and MSK test 
datasets for 31-gene signature 












































From the Table 3-11 above, it can be seen that the log-rank p-values for 31 gene signature were 
very significant in all the datasets. 
Since all the above methods showed good results for 31 gene signature, it was considered to be 
further validated. Though the 21 gene signature had almost good results, 31 gene signature was 
considered as it included all the 21 genes from the 21 gene signature. 
Since 31 gene signature performed well in the above validation techniques, we tried to evaluate 
the performance of just the Stage I patients predicted from the above model.  
There were 157 patients in the Training dataset who belonged to Stage I and among them 83 
patients were predicted as Good Prognosis and 74 patients were predicted as Poor Prognosis. The 
log-rank p-value and the KM plot shown in Figures 3-7 below show that Stage I is very 
significant in the Training dataset. 
 
Figure 3-7: KM plot of Training data for Stage I patients 
 
There were 56 patients in DFCI dataset who belonged to Stage I and among them 24 patients 




63 patients in MSK dataset who belonged to Stage I and among them 41 patients were predicted 
as Good Prognosis and 22 patients were predicted as Poor Prognosis.  
Thus it can be seen from the Figures 3-8 and 3-9 below that the stratification for Stage I patients 
was very significant and that the log-rank p-values were very significant. 
 




Figure 3-9: KM plot of MSK data for Stage I 
patients 
Then the Stage I was further split in to Stage IA and Stage IB patients and the same analysis was 
performed.  
There were 76 patients in the training dataset (UM+HLM) who belonged to Stage IA and among 
them 48 patients were predicted as Good Prognosis and 28 patients were predicted as Poor 
Prognosis. Thus the training dataset (UM+HLM) was significant for Stage IA group according to 





Figure 3-10: KM plot of Training data for Stage IA patients 
 
There were 11 patients in DFCI dataset who belonged to Stage IA and among them 5 patients 
were predicted as Good Prognosis and 6 patients were predicted as Poor Prognosis. There were 
27 patients in MSK dataset who belonged to Stage IA and among them 18 patients were 
predicted as Good Prognosis and 9 patients were predicted as Poor Prognosis.  
According to the KM plots and log-rank p-values shown in Figures 3-11 and 3-12, Stage IA of 
the Test sets (DFCI and MSK) was not as significant as Stage I, which might be because of the 





Figure 3-11: KM plot of DFCI data for Stage IA 
patients 
 
Figure 3-12: KM plot of MSK data for Stage IA 
patients 
 
There were 81 patients in the training dataset (UM+HLM) who belonged to Stage IB and among 
them 35 patients were predicted as Good Prognosis and 46 patients were predicted as Poor 
Prognosis as shown in the KM plot in Figure 3-13 below.  
 
Figure 3-13: KM plot of Training data for Stage IB patients 
 
There were 45 patients in DFCI dataset who belonged to Stage IB and among them 19 patients 




36 patients in MSK dataset who belonged to Stage IB and among them 23 patients were 
predicted as Good Prognosis and 13 patients were predicted as Poor Prognosis.  
Thus Stage IB in DFCI and MSK datasets was significant from the log-rank p-values and KM 
plots in the Figures 3-14 and 3-15 shown below. 
 




Figure 3-15: KM plot of MSK data for Stage IB 
patients 
3.4. Summary 
This chapter provided a flow chart of the methodology used and discussed how the gene 
signatures were identified using implication networks. The details of the datasets used were 
mentioned and all the procedures used and the results obtained by the methodology were also 
summarized. The major cancer hallmarks which were used to identify signatures were described 
and all the gene signatures identified were given. Survival analysis results were provided for all 
the datasets. Thus the 31 gene signature was considered to be the most significant from all the 







In the earlier chapter, details were provided on the identification of gene signatures. This chapter 
discusses about the validation techniques that were used and all the processing that was done on 
the datasets. Details about the gene signature were provided. Prognostic validation performed 
done using techniques like Concordance probability estimates and Gene set enrichment analysis. 
Clinical evaluation was conducted using Multivariate COX proportional hazards model. 
Topological validation was done by comparing the interactions from implication networks with 
interactions from Bayesian networks built using Tetrad IV. Various web based tools were also 
used to confirm the presence and the significance of the interactions from implication networks. 
All the results that were obtained from Prognostic validation, Clinical evaluation, and 
Topological validation are provided. 
4.2 Gene Signature Details and Differentially Expressed genes 
Since the 31 gene signature was considered to be the most prognostic signature, the details of the 
31 genes were provided. The details include the chromosome locations, molecular functions and 
classifications that have been confirmed by Dr. Yong Qian from The National Institute for 












Unknown   215642_at  10q23.33   
Unknown   217470_at  4q35.2   




ACTR8  218658_s_at 3  Structure 
ADAM3B  217237_at  16q12.1   
BCDIN3  219798_s_at 7q22.1  S‐adenosyl‐L‐methionine‐dependent 
methyltransferase 
Metabolism 
C1orf68  217087_at  1q21.3   
CAP2  212554_at  6p22.3   
CDKN2B  207530_s_at 9p21  Cell growth regulator Oncogene 
DAG1  205417_s_at 3p21  Link the cytoskeleton to the 
extracellular matrix 
Structure 
DEFA5  207529_at  8pter‐p21 Host defense Immunity 
dJ222E13.2  214828_s_at 22q13.2   
ESM1  208394_x_at  5q11.2  Lung endothelial cell‐leukocyte 
interactions 
Signaling transduction
FABP7  216192_at  6q22‐q23  Fatty acid uptake, transport, and 
metabolism 
Metabolism 
GAL3ST1  205670_at  22q12.2  Sulfotransferase activity  Metabolism 
H2AFB3  214412_at  Xq28  A protein component  of histone Structure 
LOR  207720_at  1q21  A major protein component of the 
cornified cell envelope  
Structure  
PALM  203859_s_at 19p13.3  control of cell shape Structure 








PRKACA  216234_s_at 19p13.1  Protein kinase Signaling transduction 
PRR4  204919_at  12p13  Protection in eye Immunity 
RPL27A  203034_s_at 11p15  A component of  ribosome Metabolism  
SAMD4B  220457_at  19q13.2   
SCGB2A2  206378_at  11q13   




SSFA2  202506_at  2q31.3   
TAC3  219992_at  12q13‐q21 Vasodilators and secretagogues Signaling transduction
TEX11  221259_s_at Xq13.1   
TM4SF20  220639_at  2q36.3   




To find the differentially expressed genes from the 31 gene signature, T-tests and fold changes 
were calculated. To perform the Fold change analyses, data should be distributed normally. Since 
the data we have been using is not normally distributed, we log transform the data to change it to 
the required form. The histograms of a few genes over all the samples and histograms of a few 
samples over all the genes were plotted as shown below in the Figures 4-1 and 4-2. 
 
Figure 4-1: Histograms for 4 genes over all the 442 samples of data showing that the log transformed data is 
less skewed than data which was not log transformed 
 
Figure 4-2: Histograms for 4 samples, each from one dataset over all the 22215 genes of data showing that the 





To find the differentially expressed genes, T-tests and fold changes analyses were performed. 
Their results for the 31 genes are shown below in Table 4-2 and Table 4-3. The data for all the 
442 samples (UM+HLM+DFCI+MSK) was considered together. T-tests for the 31 genes with 
respect to the different predictive factors such as Stage, Tumor Differentiation and Lymph node 
metastases are performed. The genes that were significant in T-test (≤ 0.05) are shown with a star 
in the plots shown for fold changes further below.  
There were three stages (1, 2 and 3) and calculations were conducted with respect to stage 1 
samples. For analysis with Stage, T-tests for Stage 2 to Stage 1 had four significant genes and T-
tests for Stage 3 to Stage 1 also had four significant genes. They are shown with a star in the 
Figure 4-3 below.  
There were three kinds of tumor differentiation (well, poorly and moderate differentiated) and 
the calculations were performed with respect to well differentiated samples. For analysis with 
Tumor Differentiation, T-tests for Moderate differentiation to Well differentiation had six 
significant genes and T-tests for Poor Differentiation to Well differentiation had eight significant 
genes. They are shown with a star in the Figure 4-4 below.  
There were two kinds of lymph node metastases (LN- and LN+) where calculation was done 
with respect to LN- samples. For analysis with Lymph node metastases, T-tests for lymph node 
positive to lymph node negative had no significant genes. All the results obtained for T-tests are 





Table 4-2: T-test outputs for different predictors such as Stage (Stage-2 to Stage-1 and Stage-3 to Stage-1), 
Tumor differentiation (Moderate to Well and Poor to Well) and Lymph node metastases (LN+ to LN-) 



















215642_at  0.441814  0.145264 0.857738 0.738474  0.322506
217470_at  0.655542  0.338437 0.661369 0.131298  0.393442
ACTL6B  0.727608  0.607288 0.768965 0.173359  0.864637
ACTR8  0.033593  0.750247 0.551963 0.856646  0.055846
ADAM3B  0.938388  0.068125 0.013012 0.000868  0.288685
BCDIN3  0.858558  0.223081 0.289013 0.802365  0.648078
C1orf68  0.022491  0.700184 0.169695 0.012192  0.193197
CAP2  0.768851  0.457084 0.571463 0.000115  0.96312
CDKN2B  0.446325  0.945302 0.264274 0.894857  0.307397
DAG1  0.542864  0.775556 0.97073 0.350751  0.855356
DEFA5  0.259804  0.189907 0.160888 0.180041  0.729967
dJ222E13.2  0.595055  0.729298 0.15501 0.765353  0.262961
ESM1  0.039148  0.280311 0.000309 0.000389  0.050772
FABP7  0.838281  0.818263 0.713371 0.193622  0.929565
GAL3ST1  0.727634  0.01859 0.039144 0.002981  0.57002
H2AFB3  0.322762  0.528597 0.743628 0.448308  0.514133
LOR  0.469576  0.575702 0.987738 0.124489  0.998675
PALM  0.267144  0.685552 0.825739 0.884183  0.557783
PCDHB3  0.652335  0.085702 0.029541 0.067242  0.603537
PCDHGA3  0.354072  0.105162 0.32659 0.93396  0.470739
PRKACA  0.16995  0.224605 0.263827 0.023981  0.844798
PRR4  0.765668  0.02991 0.194364 0.109536  0.742261
RPL27A  0.553478  0.011909 0.079101 0.962865  0.378543
SAMD4B  0.877808  0.295199 0.405373 0.134323  0.935369
SCGB2A2  0.242397  0.298675 0.94019 0.769274  0.493917
SLC22A11  0.34981  0.770405 0.930257 0.986529  0.657845
SSFA2  0.024944  0.051833 0.366235 0.005074  0.330087
TAC3  0.258139  0.087507 0.903948 0.249307  0.743349
TEX11  0.164771  0.161557 0.006716 0.228346  0.695372
TM4SF20  0.858663  0.80129 0.654298 0.818728  0.993537






Fold Changes for the 31 genes with respect to the different predictive factors such as Stage, 
Tumor Differentiation and Lymph node metastases are shown below in Figures 4-3, 4-4, and 4-5 
respectively. The genes that have fold changes ≥2 are considered to be upregulated and the genes 
that have fold changes ≤0.5 are considered to be down regulated. There were no genes that were 
upregulated or down regulated according to Fold changes.  
There were three stages (1, 2 and 3) and fold change calculations were conducted with respect to 
stage 1 samples which are shown in Figure 4-3. There were three kinds of tumor differentiation 
(well, poorly and moderate differentiated) and the calculations were performed with respect to 
well differentiated samples which are shown in Figure 4-4. There were two kinds of lymph node 
metastases (LN- and LN+) where calculation was done with respect to LN- samples as shown in 





Table 4-3: Fold changes for different predictors such as Stage (Stage-2 to Stage-1 and Stage-3 to Stage-1), 
Tumor differentiation (Moderate to Well and Poor to Well) and Lymph node metastases (LN+ to LN-) 


























215642_at  1.024592  0.864067 0.96636 1.168628  1.047483
217470_at  0.867161  1.641676 1.585661 0.622946  0.893683
ACTL6B  0.559918  1.620453 1.347857 0.609641  0.722991
ACTR8  0.378939  90.51783 42.39918 0.113063  0.236895
ADAM3B  0.559942  6.168879 2.771941 1.491585  0.854981
BCDIN3  4.87E‐05  6.66E+12 84896277 2.63E‐09  0.000392
C1orf68  0.023504  317.101 51.31794 0.033108  0.141262
CAP2  0.369338  72610.67 58115.3 37.67143  0.757832
CDKN2B  0.260977  2.634748 2.371027 0.473173  0.43117
DAG1  0.000011  9.95E+23 5.51E+18 2.51E‐09  2.44E‐05
DEFA5  6.41E‐19  282.4736 135.1423 6.94E‐11  3.8E‐13
dJ222E13.2  0.030751  230.7319 13.75698 0.023975  0.032192
ESM1  0.000932  254493.4 9091.178 0.023702  0.034733
FABP7  6.18482  1673.235 0.253757 0.017357  4.768529
GAL3ST1  0.066054  228.7593 19.25724 2.281099  0.28678
H2AFB3  0.473328  4.360512 7.784657 0.856106  0.494805
LOR  0.888696  3.77847 1.710162 0.877704  1.01584
PALM  0.237886  7.77E+08 1544293 0.000466  0.101454
PCDHB3  0.028522  450103.8 150.0798 3.77E‐05  0.036493
PCDHGA3  0.820507  4.22E+18 502.1335 1.06E‐11  0.207464
PRKACA  0.061531  131.563 18.31498 0.017633  0.112883
PRR4  2.905829  1447.149 143.6872 0.054177  2.557132
RPL27A  1.21E‐82  3.3E+171 2.6E+124 2.66E‐58  1.99E‐69
SAMD4B  0.500379  7.762561 0.908299 0.304523  1.188885
SCGB2A2  0.95827  1.18309 0.922625 0.512091  0.908788
SLC22A11  0.759165  1.032998 2.002644 0.775557  0.717989
SSFA2  24945.98  2.12E+16 5.86E+24 1.584037  0.000148
TAC3  5.948372  2663.06 37.05733 0.0004  3.777423
TEX11  0.093164  233.0746 64.09065 0.249336  0.221878
TM4SF20  2.79735  14.56566 2217.304 408.6983  2.20726





Figure 4-3: Fold changes of the 31 genes for Stage, where blue color bars represent fold change of stage 2 
w.r.t. stage 1 and red color bars represent fold change of stage 3 w.r.t. stage 1 and genes with stars on the top 
represent the significant genes from T-test with p≤0.05. 
 
 
Figure 4-4: Fold changes of the 31 genes for Tumor Differentiation, where blue color bars represent fold 
change of Moderate differentiation w.r.t. Well differentiation and red color bars represent fold change of 
Poor differentiation w.r.t. Well differentiation and genes with stars on the top represent the significant genes 






Figure 4-5: Fold changes of the 31 genes for Lymph node metastases, where blue color bars represent fold 
change of lymph node positive w.r.t. lymph node negative.  
 
4.3 Prognostic Validation 
Prognostic Validation is done using metrics such as Overall Accuracy, Concordance Probability 
Estimate (CPE), and Gene Set Enrichment Analysis (GSEA). Our model is also validated using 
other methods in Weka. Now only the 31 gene signature is considered for validation. 
4.3.1 Overall Accuracy: 
Training data: 
Overall Accuracy of the Training data for 31 gene signature was calculated with 3 years as a 
cutoff. Poor prognosis corresponds to samples that were dead by the end of the cut off period (in 
actual data) or were predicted as high risk through the model (in predicted data). Similarly, good 
prognosis corresponds to the samples that had their status to be living by the end of cutoff period 
(in actual data) or were predicted as low risk through the model (in predicted data). The 




censored cases were ignored. There were 67 cases in Training data which belonged to Poor 
prognosis in both actual data as well as the predicted data which constituted the True Positives. 
Similarly there were 88 cases which belonged to Good prognosis in both actual and predicted 
data which constituted the True Negatives. Similarly False Positives and False Negatives were 
determined for the Training data which are shown below in the Table 4-4 along with the 
sensitivity, specificity and overall accuracy. The contingency table for the actual data versus the 
predicted data is shown below. 
 
Table 4-4: Sensitivity, Specificity and Overall Accuracy of Training data calculated from contingency table 
Training  Actual data  Predicted data Sensitivity Specificity Overall Accuracy








Overall Accuracy of the DFCI data for 31 gene signature was calculated with 3 years as a cutoff. 
Poor prognosis corresponds to samples that were dead by the end of the cut off period (in actual 
data) or were predicted as high risk through the model (in predicted data). Similarly, good 
prognosis corresponds to the samples that had their status to be living by the end of cutoff period 
(in actual data) or were predicted as low risk through the model (in predicted data). The 
contingency table was formed from the comparison of actual data with the predicted data. The 5 




prognosis in both actual data as well as the predicted data which constituted the True Positives. 
Similarly there were 26 cases which belonged to Good prognosis in both actual and predicted 
data which constituted the True Negatives. Similarly False Positives and False Negatives were 
determined for the DFCI data which are shown below in the Table 4-5 along with the sensitivity, 
specificity and overall accuracy. The contingency table for the actual data versus the predicted 
data is shown below. 
 
Table 4-5: Sensitivity, Specificity and Overall Accuracy of DFCI data calculated from contingency table 
DFCI  Actual data  Predicted data Sensitivity Specificity Overall Accuracy








Overall Accuracy of the MSK data for 31 gene signature was calculated with 3 years as a cutoff. 
Poor prognosis corresponds to samples that were dead by the end of the cut off period (in actual 
data) or were predicted as high risk through the model (in predicted data). Similarly, good 
prognosis corresponds to the samples that had their status to be living by the end of cutoff period 
(in actual data) or were predicted as low risk through the model (in predicted data). The 
contingency table was formed from the comparison of actual data with the predicted data. The 10 
censored cases were ignored. There were 19 cases in Training data which belonged to Poor 
prognosis in both actual data as well as the predicted data which constituted the True Positives. 




data which constituted the True Negatives. Similarly False Positives and False Negatives were 
determined for the MSK data which are shown below in the Table 4-6 along with the sensitivity, 
specificity and overall accuracy. The contingency table for the actual data versus the predicted 
data is shown below. 
 
Table 4-6: Sensitivity, Specificity and Overall Accuracy of MSK data calculated from contingency table 
MSK  Actual data  Predicted data Sensitivity Specificity Overall Accuracy








CPE [29] was calculated for the 31 gene signature using the function “phcpe” from R for both 
the test datasets DFCI and MSK. The outputs of the function were compared with the model 
from Shedden et al [20] as shown in Table 4-7.  
Table 4-7: Comparison of 31 gene signature with model from Shedden et al [20] on both the Test datasets 
where log-rank p-values, hazard ratios, and confidence intervals were obtained from the CPE package which 
use the risk scores of the entire signature as input 
DFCI dataset  Hazard ratio with 95% CI  Log‐rank p‐value  CPE 
For model from Shedden et al [20]  1.83 [1.24, 2.70] 0.002  0.63
For 31 gene signature with Risk Scores  2.68 (1.88, 3.82] 5.30E‐08  0.71
MSK dataset  Hazard ratio with 95% CI  Log‐rank p‐value  CPE 
For model from Shedden et al [20]  1.76 [1.20, 2.60] 0.003  0.62
For 31 gene signature with Risk Scores  3.31 [2.11, 5.2] 2.10E‐07  0.70
The hazard ratios for both the test datasets were higher for the 31 gene signature which shows 




confidence intervals are shown by error bars in the Figure 4-6. The log-rank p-values of the test 
datasets are much lower for the 31 gene signature when compared to the results from the model 
from Shedden et al [20] as shown in Figure 4-7 which shows that they are highly significant. The 
CPE values are supposed to be higher than 0.5 and as high as possible. Figure 4-8 shows that the 
31 gene signature had much higher CPE values than the model from Shedden et al [20]. This 
proves that the 31 gene signature has better performance in terms of CPE, hazard ratios, and log-
rank p-values when compared to the model from Shedden et al [20]. 
 
Figure 4-6: Hazard ratios and 95% Confidence 
Intervals (obtained from the CPE package which 
use the risk scores of the entire signature as input) 
shown along with error bars for 31gene signature 
and the model from Shedden et al. 
 
 
Figure 4-7: Comparison of p-values (obtained 
from the CPE package which use the risk scores of 
the entire signature as input) for 31 gene signature 






Figure 4-8 : Concordance Probability Estimates compared between 31 gene signature and the model from 
Shedden et al. 
 
4.3.3 Gene Set Enrichment Analysis(GSEA) 
To run GSEA [30], gene expression values of all the genes were taken. Since it is better to have 
as many samples as possible, the training (UM+HLM) and test datasets (DFCI and MSK) were 
combined to form the 442 samples dataset. The samples were then assigned a class and there 
were a few censored cases which did not fall in to either of the classes. Hence there were 358 
samples after censoring 84 samples. Three files are loaded into GSEA as shown in Figure 4-9: 
first one is the expression dataset file which contains the gene expression values of the entire set 
of genes; second one is the phenotype labels file which includes the phenotype labels associated 






Figure 4-9: Screenshot for loading data in to GSEA 
 
We used 15 gene sets which included our 31 gene dataset. The remaining 14 gene sets were 
extracted from different published papers. The sizes of the datasets used and the sizes that were 
identified by GSEA are shown in the Table 4-8 below. 
Table 4-8: Different signatures used to compare the performance of the 31 gene signature in GSEA 





















Figure 4-10: Screenshot showing the Basic fields in running GSEA 
 
The datasets were collapsed to gene symbols and HG_U133A chip platform was used. 1000 
permutations were done on phenotypes as shown in Figure 4-10. Ratio of classes was taken as a 
metric for ranking the genes and the real values of the genes were considered as shown in 
Figures 4-11 and 4-12. 
 






Figure 4-12: Screenshot showing the selection of sorting the gene list based on their real values 
 
There were only 14 gene sets as one of the gene set which had more than 500 genes was filtered 
out from the analysis. Out of the 14 gene sets, 9 gene sets were enriched in phenotype “Good”. 
In other words they were upregulated in Good prognosis as shown in Table 4-9. There were 4 
gene sets among these 9 gene sets which were significant at FDR<25% which includes the 
31genes dataset. Out of the 14 gene sets, there were 5 gene sets which were enriched in the 
phenotype “Poor”. One of them is significantly enriched at FDR<25% as shown in Table 4-10. 
Table 4-9: Different signatures Enriched in phenotype “Good”, which include the 31 gene signature 
SIGNATURE 
INDEX 




1  SHEDDEN_MD [20] 32 0.597466 2.385339 0 0 0 
2  SHEDDEN_MC[20] 22 0.558553 2.172679 0 0.006652 0.013 
3  BHATTACHARJEE_150G [55] 124 0.2782 1.553199 0.044595 0.178669 0.41 
4  IMPLICATION_31G 25 0.992265 1.518779 0.255459 0.218715 0.587 
5  GUO_35G [59] 26 0.228604 1.359544 0.12989 0.28394 0.845 
6  RAPONI_50G [56] 39 0.221071 1.393075 0.156566 0.313299 0.822 
7  CHEN_5G [52] 5 0.435005 1.138269 0.299257 0.370527 0.965 
8  SHEDDEN_MB [20] 38 0.172793 1.148412 0.299652 0.41296 0.962 
9  POTTI_133G [51] 125 0.069968 0.786085 0.694957 0.681874 0.999 
Table 4-10: Different signatures Enriched in phenotype “Poor” 
SIGNATURE 
INDEX 




10  SHEDDEN_MH [20] 223 ‐0.51735 ‐2.33102 0 0.00139 0.002 
11  LU_64G [58] 59 ‐0.14059 ‐1.22657 0.236994 0.551122 0.664 
12  BEER_50G [53] 44 ‐0.18432 ‐0.99556 0.416422 0.740632 0.897 
13  BOUTROS_6G [54] 6 ‐0.2156 ‐0.72 0.826552 0.799505 0.989 





Figure 4-13: Enrichment score plot for the 31 gene 
signature picked from implication networks which 
shows the Enrichment profile on the top and the 
ranked list metric on the bottom  
 
 
Figure 4-14: Plot showing the Nominal 
Enrichment Scores, False Discovery Rates and 
Nominal P-values for all the signatures with 
Signature index of each signature from Table 4-9 
and 4-10. Index 4 represents the 31-gene signature 
from implication networks
 
The Figures 4-13 above shows the Enrichment score plot for the 31 gene signature and Figure 4-
14 shows the comparison plot for nominal p-values and FDR with respect to NES for all the 
signatures used, highlighting the 31 gene signature. 
4.3.4 Comparison of model with other classification methods using WEKA 
The model used to classify the samples in to two groups was compared against randomly picked 
classifiers in Weka. Five classifiers were considered which are Random Tree Classifier, Support 
Vector Machine (SVM or SMO) classifier, K-nearest neighbors (IBK) classifier, Multilayered 




The actual classification of the groups based on the survival period and status of post operative 
survival was compared with the classifications performed by the above mentioned classifiers. 
The classification accuracies using nearest point classification in Cox model for implication 
networks were calculated from the sensitivity, specificity, and overall accuracy measures 
mentioned in the previous sections. Bayesian networks generated from TETRAD IV were also 
compared for overall accuracies. 
The comparison was performed for 5 year survival on the Training dataset (ULM/HLM). This 
dataset had 229 samples after 27 samples were censored. The results are given in the Table 4-11 
below. It can be seen that the Cox model had the best classification accuracy. The sensitivity and 
specificity values were also calculated along with the overall accuracy. Significance test was 
conducted on the accuracies obtained to get the p-values. The significance of all the other models 
was calculated with accuracy of the Cox model as reference. If the p-values are small they imply 
that the NULL hypothesis (here equal significance of the two compared overall accuracies) is 
rejected and that the Alternative hypothesis (significance of larger overall accuracy > 
significance of smaller overall accuracy) is strongly supported. Since all the p-values are very 
small, it is obvious that the Cox model is highly significant when compared to other models. 
These classifications were used to find the Concordance Probability Estimates, log-rank p-






Table 4-11: Comparison of classification accuracies of various methods from Weka with Cox model on 















Random Tree  121  108 56.8% 48.1% 52.8%  2.48 0.006
SMO (or SVM)  132  97 72.0% 40.4% 57.6%  1.45 0.073
IBK  129  100 58.4% 53.8% 56.3%  1.73 0.042
Multilayered 
Perceptron(Neural) 
132  97 64.0% 50.0% 57.6%  1.45 0.073
Bayes Net  120  109 90.4% 6.7% 52.4%  2.56 0.005
Bayesian Networks 
using TETRAD IV 133 96 65.6% 49.0% 58.1% 1.34 0.090
Implication Networks 
‐ COX model 
147  82 66.4% 61.5% 64.2%  − −
 
The Concordance Probability Estimates, log-rank p-values, hazard ratios, and the confidence 
interval calculated from classifications from various models on training dataset (ULM/HLM) are 
shown below in Table 4-12. The CPE values are supposed to be higher than 0.5 and the higher 
they are, the better is the model. The log-rank p-values of the models must be less than 0.05 and 
the lesser they are, the more significant the model is considered to be. The hazard ratios should 
be as high as possible and the 95% confidence intervals should not contain 1 in their range. The 
Cox model had highly significant results when compared to the other techniques. 
Table 4-12: Comparison of Concordance Probability Estimates, log-rank p-values (obtained from the CPE 
package with risk scores of the entire signature as input), hazard ratios (based on 5-year cutoff) and 
confidence intervals (obtained from the CPE package with risk scores of the entire signature as input) of 





Random Tree  0.524456 0.535865 1.1 [0.809, 1.5]
SMO (or SVM)  0.539067 0.157513 1.27 [0.909, 1.77]




Multilayered Perceptron(Neural)  0.57637 0.053659 1.36 [0.992, 1.87]
Bayes Net  0.516962 0.816327 0.934 [0.53, 1.65]
Implication Networks‐COX model  0.7123937 3.90E‐08 2.48 [1.79, 3.42]
 
Since the training dataset had good results, we tried to validate the model on the testing datasets. 
The classification from survival time and status was used as actual classification for the DFCI 
test dataset. This dataset had 64 samples after 18 samples were censored. The classification 
results for DFCI dataset for various classifiers used in Weka are shown below in comparison 
with the Cox model in Table 4-13. Bayesian networks generated from TETRAD IV were also 
compared for overall accuracies. The sensitivity and specificity values were also calculated along 
with the overall accuracy. Significance test was conducted on the accuracies obtained to get the 
p-values. The significance of all the other models was calculated with accuracy of the Cox model 
as reference. If the p-values are small they imply that the NULL hypothesis (here equal 
significance of the two compared overall accuracies) is rejected and that the Alternative 
hypothesis (significance of larger overall accuracy > significance of smaller overall accuracy) is 
strongly supported. Since all the p-values are very small, it is obvious that the Cox model is 
highly significant when compared to other models. 
Table 4-13: Comparison of classification accuracies of various methods from Weka with Cox model on 















Random Tree  34  30 64.3% 44.4% 53.1%  1.44 0.075
SMO (or SVM)  27  37 92.9% 2.8% 42.2%  2.66 0.004
IBK  26  38 39.3% 41.7% 40.6%  2.83 0.002
Multilayered 
Perceptron (Neural) 
27  37 92.9% 2.8% 42.2%  2.66 0.004





using TETRAD IV 30 34 60.7% 36.1% 46.9% 2.13 0.017
Implication 
Networks‐Cox Model 
42  22 92.9% 44.4% 65.6%  − −
 
The Concordance Probability Estimates, log-rank p-values, hazard ratios, and the confidence 
interval calculated from the model on DFCI dataset are shown below. All the instances in Bayes 
Net were classified to the same group (Poor prognosis) and hence calculation of the parameters 
was not possible (NA). This is because the calculation of parameters requires at least two 
different groups. The CPE values are supposed to be higher than 0.5 and the higher they are, the 
better is the model. The log-rank p-values of the models must be less than 0.05 and the lesser 
they are, the more significant the model is considered to be. The hazard ratios should be as high 
as possible and the 95% confidence intervals should not contain 1 in their range. From the results 
shown below in Table 4-14, it can be concluded that Cox model had much significant results 
when compared to other techniques. 
Table 4-14: Comparison of Concordance Probability Estimates, log-rank p-values (obtained from the CPE 
package with risk scores of the entire signature as input), hazard ratios (based on 5-year cutoff) and 
confidence intervals (obtained from the CPE package with risk scores of the entire signature as input) of 





Random Tree  0.543057 0.620414 1.19 [0.597, 2.36]
SMO (or SVM)  0.693209 0.319597 0.443 [0.106, 1.85]
IBK  0.600628 0.230398 0.665 [0.34, 1.3]
Multilayered Perceptron(Neural)  0.693209 0.319597 0.443 [0.106, 1.85]
Bayes Net  NA NA NA 





The classification from survival time and status was used as actual classification for the MSK 
test dataset. This dataset had 65 samples after 39 samples were censored. The classification 
results for MSK dataset for various classifiers used in Weka are shown below in Table 4-15. 
Bayesian networks generated from TETRAD IV were also compared for overall accuracies. The 
sensitivity and specificity values were also calculated along with the overall accuracy. 
Significance test was conducted on the accuracies obtained to get the p-values. The significance 
of all the other models was calculated with accuracy of the Cox model as reference. If the p-
values are small they imply that the NULL hypothesis (here equal significance of the two 
compared overall accuracies) is rejected and that the Alternative hypothesis (significance of 
larger overall accuracy > significance of smaller overall accuracy) is strongly supported. Since 
all the p-values are very small, it is obvious that the Cox model is highly significant when 
compared to other models. 
Table 4-15: Comparison of classification accuracies of various methods from Weka with Cox model on 















Random Tree  35  30 67.6% 38.7% 53.8%  1.44 0.075
SMO (or SVM)  31  34 2.9% 96.8% 47.7%  2.13 0.017
IBK  26  39 29.4% 51.6% 40.0%  2.99 0.001
Multilayered 
Perceptron(Neural) 
34  31 100.0% 0.0% 52.3%  1.61 0.054
Bayes Net  34  31 100.0% 0.0% 52.3%  1.61 0.054
Bayesian Networks 
using TETRAD IV 33 32 58.8% 41.9% 50.8% 1.78 0.037
Implication Networks‐
COX model 





The log-rank p-values, CPE, hazard ratios, and the confidence interval calculated from the model 
on MSK dataset are shown below. All the instances in Multilayered Perceptron and Bayes Net 
were classified to the same group (Poor prognosis) and hence calculation of the parameters was 
not possible (NA). This is because the calculation of parameters requires at least two different 
groups. The CPE values are supposed to be higher than 0.5 and the higher they are, the better is 
the model. The log-rank p-values of the models must be less than 0.05 and the lesser they are, the 
more significant the model is considered to be. The hazard ratios should be as high as possible 
and the 95% confidence intervals should not contain 1 in their range. From the results shown 
below in Table 4-16, it can be concluded that Cox model had much significant results when 
compared to other techniques. 
 
Table 4-16: Comparison of Concordance Probability Estimates, log-rank p-values (obtained from the CPE 
package with risk scores of the entire signature as input), hazard ratios (based on 5-year cutoff) and 
confidence intervals (obtained from the CPE package with risk scores of the entire signature as input) of 





Random Tree  0.539067 0.651084 1.17 [0.59, 2.32]
SMO (or SVM)  0.538504 0.882016 1.17 [0.16, 8.53]
IBK  0.548117 0.565333 0.824 [0.425, 1.6]
Multilayered Perceptron(Neural)  NA NA NA
Bayes Net  NA NA NA
Implication Networks‐COX model  0.782544 0.00019 3.6 [1.84, 7.05]
 
Thus all the results above show that the Cox model predicted the outcomes with best 






Clinical evaluation was done by comparing various predictive factors such as Age, Gender, 
Lymph node metastasis, Tumor size, etc with the risk scores from our model. This is done using 
multivariate Cox proportional hazards model. 
Multivariate Analysis on Cox proportional hazards model 
Multivariate analysis was done using the Cox proportional hazards model to compare the 
significance of the risk scores from 31 gene signature with the other pathological factors. For 
multivariate analysis, the risk scores of the 31 gene signature obtained in Cox model earlier were 
used as a predictor. Mostly used covariates such as Age, Gender, Lymph node Metastasis, and 
Tumor size were used with the risk scores of 31 gene predictors as shown in Table 4-17. In this 
table, the other predictors were fit in to Cox model without the risk scores and then they were 
again fit in to Cox model with the risk scores included. Both the analyses were compared which 
showed that the addition of risk scores to other predictors made the significance of other 
predictors to decrease and that the risk scores of our model had the most significant p-value.  

















*Age was a binary variable (0 for an age less than 60 years and 1 for an age of 60 years or greater); Gender 
was a binary variable (0 for Male and 1 for Female); Lymph node Metastasis was a binary variable (0 for N0-
stage and 1 for all other N-stages and missing values); Tumor size was a binary variable (0 for T0-stage and 1 
for all other T-stages and missing values); Risk score was a continuous variable. 
¥ CI denotes Confidence interval. 
 
To perform a complete and comprehensive analysis on the pathological factors of Non-Small 
Cell Lung Cancer, all the other covariates like Race, Smoking status, and Tumor grade were 
added to the above covariates to find the log-rank p-values and Hazard ratios as shown in Table 
4-18. Again analyses with and without risk scores was done and it can be seen that 31 gene 
predictors are most significant. The smoking status can be ignored as it has a group of unknown 
samples which would not allow the correct prediction of the entire group. The descriptions of 





Table 4-18: Multivariate Cox Proportional Analysis of Age, Gender, Race, Smoking Status, Lymph node 
Metastasis, Tumor size, Tumor grade and Risk Score* 






























*Age was a binary variable (0 for an age less than 60 years and 1 for an age of 60 years or greater); Gender 
was a binary variable (0 for Male and 1 for Female); Race was a binary variable (Other relative to 
Black/African American, White relative to Black/African American; Other includes a few Native 
Hawaiian/Pacific Islander, Asian and unknown); Smoking status was a binary variable (Smokers relative to 
Non-Smokers and Unknown status relative to Non-Smokers); Lymph node Metastasis was a binary variable 
(0 for N0-stage and 1 for all other N-stages and missing values); Tumor size was a binary variable (0 for T0-
stage and 1 for all other T-stages and missing values); Tumor grade was a binary variable (Poorly 
differentiated relative to moderately differentiated and Well differentiated relative to moderately 
differentiated); Risk score was a continuous variable. 





To derive the biological insight using curated databases, topological validation was performed on 
the prognostic signature obtained from prediction logic based implication networks. This 
validation also required the comparison of the biological relevance of the interactions present in 
the implication network with a currently used network such as Bayesian network. There are 
many techniques for structural validation of the gene signature.  
In prognostic validation, the best probe was considered based on the minimum p-value after 
fitting in to Cox model. But in structural validation, the average of all the duplicate probes was 
taken and was used for the analysis. The different structural validation techniques used include 
Prodistin, Kegg, NCI pathways, PubMed interactions, Matisse, String 8, Ingenuity Pathway 
Analysis, and Pathway Studio. Tetrad IV was used to generate Bayesian networks which were 
compared in different aspects with the implication network. 
The implication network was built from the 31 genes and the hallmarks used to identify the 
signature.  
The gene expression data of the 22215 genes was sorted according to their gene symbols. The 
averages of the duplicate probes were taken which leaves 13658 unique genes. The 31 genes 
along with the hallmarks which were used to get the 31 gene signature were picked. Hence there 
were 31 genes plus 8 hallmarks. There were 256 samples in the Training dataset. This data is 
split in to 2 files, Metastasis (high risk) and Non-Metastasis (low risk) groups, based on the 
number of months they survived and survival status. If the number of months the patients 
survived was greater than 60 (5 years), the sample was put in Non-Metastasis group (low risk). If 




patient died, the sample was put in Metastasis group (high risk). If the number of months the 
patients survived was less than 60 months and if it was not known whether the patient died, the 
sample was censored.  
The Metastasis group (high risk) had 125 samples and the Non-Metastasis group (low risk) had 
104 samples. The remaining 27 samples were censored as shown in Table 4-19. The data in the 
files was converted in to 1’s and 0’s by partitioning based on the mean which was used to 
generate the interactions among genes.  







Training dataset  125  104  27 
DFCI dataset  28  36  18 
MSK dataset  34  31  39 
 
Interactions between genes were generated using the files which had binary data. There were 
1021 interactions from Metastasis group (high risk) and 897 interactions from the Non-
Metastasis group (low risk) as shown in Table 4-20. 
The above steps were repeated for the 31 gene signature in DFCI data set and the MSK data set.  
The DFCI dataset had 82 samples. After partitioning, there were 28 samples for Metastasis group 
(high risk) and 36 samples for Non-Metastasis group (low risk). There were 18 samples which 
were censored as shown in Table 4-19. There were 787 interactions from Metastasis group (high 




The MSK dataset had 104 samples. After partitioning, there were 34 samples for Metastasis 
group (high risk) and 31 samples for Non-Metastasis group (low risk). There were 39 samples 
that were censored as shown in Table 4-19. There were 992 interactions from Metastasis group 
(high risk) and 996 interactions from Non-Metastasis group (low risk) as shown in Table 4-20. 








Differential components are the interactions that are present in one group (high or low) but not 
present in the other group (low or high). 
The interactions from the good and poor prognosis of the Training dataset had 235 interactions in 
common. So there were 786 interactions from the Metastasis group (high risk) and 662 
interactions from the Non-Metastasis group (low risk) that were considered as the differential 
components as shown in Table 4-21. 
Similarly, the interactions from the good and poor prognosis of the DFCI dataset had 308 
interactions in common. So there were 479 interactions from the Metastasis group (high risk) and 
630 interactions from the Non-Metastasis group (low risk) that were considered as the 
differential components as shown in Table 4-21. 
Similarly, the interactions from the good and poor prognosis of the MSK dataset had 359 




637 interactions from the Non-Metastasis group (low risk) that were considered as the 
differential components as shown in Table 4-21. 
Table 4-21: Number of differential components between both the groups for the 31 genes and the 8 hallmarks 
for various datasets 
Low risk (Non-Metastasis) High risk (Metastasis) 
Differential Components from Training=662 Differential Components from Training=786 
Differential Components from DFCI=630 Differential Components from DFCI=479 
Differential Components from MSK=637 Differential Components from MSK=633 
 
After getting the differential components for each dataset, the interactions that were common 
among every two datasets and also those interactions that were common among all the three 
datasets were found.  
Among the Metastasis group (high risk), there were 81 interactions common to the differential 
components of the Training dataset and the DFCI dataset. The interactions between the genes are 
shown graphically in the Figure 4-15 below. There were 168 interactions common to the 
differential components of the Training dataset and the MSK dataset. The interactions between 
the genes are shown graphically in the Figure 4-16 below. There were 61 interactions common to 
the differential components of the DFCI dataset and the MSK dataset. The interactions between 
the genes are shown graphically in the Figure 4-17 below. The genes in yellow color are the 
Hallmarks used and the uncolored genes are the regular signature genes. There were 31 
interactions that were common to all the three datasets in the Metastasis group (high risk). The 





Figure 4-15: Differential Components common to 
Train & DFCI datasets in high risk group 
 
 
Figure 4-16: Differential Components common to 
Train & MSK datasets in high risk group 
 
 
Figure 4-17: Differential Components common to 
DFCI & MSK datasets in high risk group 
 
 
Figure 4-18: Differential Components common to 
all 3 datasets in high risk group 
Among the Non-Metastasis group (low risk), there were 96 interactions common to the 
differential components of the Training dataset and the DFCI dataset. The interactions between 
the genes are shown graphically in the Figure 4-19 below. There were 106 interactions common 
to the differential components of the Training dataset and the MSK dataset. The interactions 
between the genes are shown graphically in the Figure 4-20 below. There were 82 interactions 




interactions between the genes are shown graphically in the Figure 4-21 below. There were 27 
interactions that were common to all the three datasets in the Non-Metastasis group (low risk). 
The interactions between the genes are shown in the Figure 4-22 below.  
 
Figure 4-19: Differential Components common to 
Train & DFCI datasets in low risk group 
 
 
Figure 4-20: Differential Components common to 
Train & MSK datasets in low risk group 
 
 
Figure 4-21: Differential Components common to 
DFCI & MSK datasets in low risk group 
 
 
Figure 4-22: Differential Components common to 
all three datasets in low risk group 
All these common interactions between the three datasets are shown in the Figure 4-23 below. 




datasets in both poor and good prognosis groups. The molecular and cellular functions of these 




Figure 4-23: Differential Components common among the three datasets in both the prognosis groups where 
good prognosis corresponds to low risk group and poor prognosis corresponds to high risk group and the 
major molecular and cellular functions identified from IPA were also shown 
 
4.5.1 PRODISTIN 
PRODISTIN is web based software that functionally classifies the genes based on the protein-
protein interactions. It is based on the principle that the more two proteins share common 
interactors, the more they are functionally related. It clusters proteins in to functional classes 
depending whether they participate in the same cellular process or not. It also predicts function 
for unknown genes. 
The process started with the selection of species to Homo sapiens. Then the interaction network, 
which is a file that includes the total number of interactions and the interactions between the 




gene/protein connectivity was put as 1 as it is the minimal connectivity threshold. There were 22 
genes/proteins that were classified by the Prodistin Method (by computing Czekanowski-Dice 
distance between all possible pairs) from the uploaded network. From the 22 classified genes, 
there were 12 genes that were non-annotated based on the Functional class identification. The 
tree was drawn grouping the genes of the same functional annotation in to one class where 
functional annotations are derived from the GO terms. There were 3 different GO terms which 
are shown in the Figure 4-24 below. If there are multiple Gene Ontology terms for a single class, 
that class would be represented by a color representing one of those multiple terms. Some classes 





Figure 4-24: Clustering from interactions Common to Train and DFCI Metastasis group from PRODISTIN 
 
The terms primary metabolism and macromolecule metabolism fall in to one class which is give 
a class number 1. P-values are shown in Table 4-22. The p-values are not very significant in this 
dataset. 
Table 4-22: p-values of Gene Ontology terms identified from known classes in Common interactions among 
Train and DFCI Metastasis group from PRODISTIN 
Class Num Number of genes in each class Gene Ontology Term P-Value 
1 5 primary metabolism 0.4762 





The interaction network, which is a file that includes the total number of interactions and the 
interactions between the genes common to Training data and the MSK data in the Metastasis 
group were loaded. The gene/protein connectivity was put as 1 as it is the minimal connectivity 
threshold. There were 34 genes/proteins that were classified by the Prodistin Method (by 
computing Czekanowski-Dice distance between all possible pairs) from the uploaded network. 
From the 34 classified genes, there were 16 genes that were non-annotated based on the 
Functional class identification. The tree was drawn grouping the genes of the same functional 
annotation in to one class where functional annotations are derived from the GO terms. There 
were 10 different GO terms which are shown in the Figure 4-25 below. If there are multiple 
Gene Ontology terms for a single class, that class would be represented by a color representing 





Figure 4-25: Clustering from interactions Common to Train and MSK Metastasis group from PRODISTIN 
 
The terms cell communication, protein modification and system development fall into class 
number 1, primary metabolism and macromolecule metabolism fall in to class number 2, protein 
metabolism and cellular metabolism fall in to class number 3, signal transduction falls in to class 
number 4, and morphogenesis falls in to class number 7. P-values are shown in Table 4-23. The 




Table 4-23: p-values of Gene Ontology terms identified from known classes in Common interactions among 
Train and MSK Metastasis group from PRODISTIN 
Class Num Number of genes in each class Gene Ontology Term P-Value 
1 5 cell communication 0.3921 
1 5 protein modification 0.2247 
1 5 system development 0.2941 
2 12 primary metabolism 0.0498 
2 12 macromolecule metabolism 0.0498 
3 8 protein metabolism 0.3628 
3 8 cellular metabolism 0.2639 
4 6 signal transduction 0.3620 
7 6 morphogenesis 0.3111 
 
The interaction network, which is a file that includes the total number of interactions and the 
interactions between the genes common to DFCI data and the MSK data in the Metastasis group 
were loaded. The gene/protein connectivity was put as 1 as it is the minimal connectivity 
threshold. There were 21 genes/proteins that were classified by the Prodistin Method (by 
computing Czekanowski-Dice distance between all possible pairs) from the uploaded network. 
From the 21 classified genes, there were 11 genes that were non-annotated based on the 
Functional class identification. The tree was drawn grouping the genes of the same functional 
annotation in to one class where functional annotations are derived from the GO terms. There 
were no GO terms identified. This is shown in Figure 4-26 below. Hence there are no p-values 
identified. If there are multiple Gene Ontology terms for a single class, that class would be 






Figure 4-26: Clustering from interactions Common to DFCI and MSK Metastasis group from PRODISTIN 
 
The interaction network, which is a file that includes the total number of interactions and the 
interactions between the genes common to Training data and the DFCI data in the Non-
Metastasis group were loaded. The gene/protein connectivity was put as 1 as it is the minimal 
connectivity threshold. There were 27 genes/proteins that were classified by the Prodistin 
Method (by computing Czekanowski-Dice distance between all possible pairs) from the 
uploaded network. From the 27 classified genes, there were 11 genes that were non-annotated 
based on the Functional class identification. The tree was drawn grouping the genes of the same 
functional annotation in to one class where functional annotations are derived from the GO 




multiple Gene Ontology terms for a single class, that class would be represented by a color 
representing one of those multiple terms. Some classes may contain other smaller classes. 
 
Figure 4-27: Clustering from interactions Common to Train &DFCI Non-Metastasis group from 
PRODISTIN 
 
The term regulation of progression through cell cycle falls in to class number 1 and cell 
organization and biogenesis falls in to class number 3. P-values are shown in Table 4-24. The p-





Table 4-24: p-values of Gene Ontology terms identified from known classes in Common interactions among 
Train &DFCI Non-Metastasis group from PRODISTIN 
Class Num Number of genes in each class Gene Ontology Term P-Value 
1 5 regulation of progression through cell cycle 0.2398 
3 5 cell organization and biogenesis 0.3916 
 
The interaction network, which is a file that includes the total number of interactions and the 
interactions between the genes common to Training data and the MSK data in the Non-
Metastasis group were loaded. The gene/protein connectivity was put as 1 as it is the minimal 
connectivity threshold. There were 31 genes/proteins that were classified by the Prodistin 
Method (by computing Czekanowski-Dice distance between all possible pairs) from the 
uploaded network. From the 31 classified genes, there were 14 genes that were non-annotated 
based on the Functional class identification. The tree was drawn grouping the genes of the same 
functional annotation in to one class where functional annotations are derived from the GO 
terms. There were 8 different GO terms which are shown in the Figure 4-28 below. If there are 
multiple Gene Ontology terms for a single class, that class would be represented by a color 





Figure 4-28: Clustering from interactions Common to Train & MSK Non-Metastasis group from 
PRODISTIN 
 
The terms primary metabolism, cellular metabolism and biopolymer metabolism fall into class 
number 1, morphogenesis, cell organization, and biogenesis fall into class number 2 and protein 
modification and cell communication fall into class number 3. P-values are shown in Table 4-25. 





Table 4-25: p-values of Gene Ontology terms identified from known classes in Common interactions among 
Train & MSK Non-Metastasis group from PRODISTIN 
Class Num Number of genes in each class Gene Ontology Term P-Value 
1 8 primary metabolism 0.1282 
1 8 cellular metabolism 0.2447 
1 8 biopolymer metabolism 0.3426 
2 6 morphogenesis 0.1573 
2 6 cell organization and biogenesis 0.2447 
3 5 protein modification 0.2884 
3 5 cell communication 0.4038 
 
The interaction network, which is a file that includes the total number of interactions and the 
interactions between the genes common to DFCI data and the MSK data in the Non-Metastasis 
group were loaded. The gene/protein connectivity was put as 1 as it is the minimal connectivity 
threshold. There were 25 genes/proteins that were classified by the Prodistin Method (by 
computing Czekanowski-Dice distance between all possible pairs) from the uploaded network. 
From the 25 classified genes, there were 10 genes that were non-annotated based on the 
Functional class identification. The tree was drawn grouping the genes of the same functional 
annotation in to one class where functional annotations are derived from the GO terms. There 
were 6 GO terms as shown in the Figure 4-29 below. If there are multiple Gene Ontology terms 
for a single class, that class would be represented by a color representing one of those multiple 





Figure 4-29: Clustering from interactions Common to DFCI & MSK Non-Metastasis group from 
PRODISTIN 
 
The terms cellular metabolism and protein metabolism fall into class number 1, intracellular 
signaling cascade, cell organization, and biogenesis fall into class number 2, and cell 
communication falls into class number 4. P-values are shown below in Table 4-26. The p-values 






Table 4-26: p-values of Gene Ontology terms identified from known classes in Common interactions among 
DFCI & MSK Non-Metastasis group from PRODISTIN 
Class Num Number of genes in each class Gene Ontology Term P-Value 
1 6 cellular metabolism 0.3730 
1 6 protein metabolism 0.3730 
2 6 intracellular signaling cascade 0.3730 
2 6 cell organization and biogenesis 0.3730 
4 8 cell communication 0.3496 
 
The interaction network, which is a file that includes the total number of interactions and the 
interactions between the genes common to all the three datasets (Train data, DFCI data and the 
MSK data) in the Metastasis group were loaded. The gene/protein connectivity was put as 1 as it 
is the minimal connectivity threshold. There were 14 genes/proteins that were classified by the 
Prodistin Method (by computing Czekanowski-Dice distance between all possible pairs) from 
the uploaded network. From the 14 classified genes, there were 7 genes that were non-annotated 
based on the Functional class identification. The tree was drawn grouping the genes of the same 
functional annotation in to one class where functional annotations are derived from the GO 
terms. There were 2 GO terms as shown in the Figure 4-30 below. If there are multiple Gene 
Ontology terms for a single class, that class would be represented by a color representing one of 





Figure 4-30: Clustering from interactions Common to 3 datasets Metastasis group from PRODISTIN 
 
The term system development falls into class number 2. P-values are not related as shown in 
Table 4-27. 
Table 4-27: p-values of Gene Ontology terms identified from known classes in Common interactions of 3 
datasets Metastasis group from PRODISTIN 
Class Num Number of genes in each class Gene Ontology Term P-Value 
2 8 system development NR 
 
The interaction network, which is a file that includes the total number of interactions and the 
interactions between the genes common to all the three datasets (Train data, DFCI data and the 
MSK data) in the Non-Metastasis group were loaded. The gene/protein connectivity was put as 1 




the Prodistin Method (by computing Czekanowski-Dice distance between all possible pairs) 
from the uploaded network. From the 18 classified genes, there were 8 genes that were non-
annotated based on the Functional class identification. The tree was drawn grouping the genes of 
the same functional annotation in to one class where functional annotations are derived from the 
GO terms. There were 4 GO terms as shown in the Figure 4-31 below. If there are multiple Gene 
Ontology terms for a single class, that class would be represented by a color representing one of 
those multiple terms. Some classes may contain other smaller classes. 
 
Figure 4-31: Clustering from interactions Common to 3 datasets Non-Metastasis group from PRODISTIN 
 
The term regulation of cell cycle falls in to class number 1, cell communication falls in to class 




Table 4-28. The cell communication and cell organization and biogenesis classes were very 
significant in this dataset. 
Table 4-28: p-values of Gene Ontology terms identified from known classes in Common interactions of 3 
datasets Non-Metastasis group from PRODISTIN 
Class Num Number of genes in each class Gene Ontology Term P-Value 
1 5 regulation of cell cycle 0.1190 
3 8 cell communication 0 
4 3 cell organization and biogenesis 0.0476 
 
4.5.2 TETRAD IV 
Tetrad IV is a software program used for simulating data from causal or statistical models. It is 
also used for estimating, testing, predicting and searching for causal or statistical models. It 
implements Bayes networks to generate graphical statistical/causal model for categorical data. 
The networks were generated using Bayesian Belief networks. The 31 genes signature were 
picked from all the three datasets and the data was partitioned in to 2 groups based on the 
survival times and status of the patients. The Metastasis group and the Non-Metastasis group 





Figure 4-32: Model used to build Bayesian networks using Tetrad IV which uses PC search, Bayes 
parametric model, ML Bayes Estimator, Bayes instantiated model, and Bayes classifier 
 
The Metastasis groups of the datasets were given as data wrappers and PC pattern search was 
used on the data. DAG in pattern graph was considered as the output which was given as the 
input to the Parametric Model which uses Bayes parametric model. The output of the Bayes PM 
and the Data were given as input to the Estimator where ML Bayes Estimator is used. This 
output was given to the Bayes instantiated model. The output of the Bayes instantiated model 
along with the data is given to the Bayes updater classifier. The networks for Train Metastasis 
group as input is shown in Figure 4-33, DFCI Metastasis group as input is shown in Figure 4-34, 
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Figure 4-36: Interactions from 31 genes and the 8 hallmarks in Train Non-Metastasis group using Tetrad IV 
 
 






Figure 4-38: Interactions from 31 genes and the 8 hallmarks in MSK Non-Metastasis group using Tetrad IV 
 
It can be seen that the 31 gene signature is connected even when using Bayesian Belief 
Networks. It can also be seen from the figures above that the implication networks are more 
connected when compared to the Bayesian Belief Networks. All the interactions from the 
Bayesian networks were also present in the interactions from implication networks. 
4.5.3 KEGG 
KEGG stands for Kyoto Encyclopedia for Genes and Genomes. As the name suggests, it is an 
encyclopedia (a large set) of genes. It is a database of 19 databases. These databases are 
categorized in to systems information (includes 4 databases), genomic information (includes 9 
databases), and chemical information (includes 6 databases). The database that was used was the 
KEGG PATHWAY database which is in the systems information to find the signal pathways of 
the 31 genes in the signature. All the genes are searched and the genes found interacting with the 




interactions that were derived from KEGG PATHWAY. The genes that are colored are the 
Hallmarks and the genes without colors are the signature genes. All the interactions extracted 
from KEGG shown below were also confirmed to be a part of the implication networks. 
 
Figure 4-39: Interactions among 31 genes and the 8 hallmarks extracted from KEGG PATHWAY database 
and all of them are confirmed with the interactions from implication networks 
 
4.5.4 NCI Pathways 
Pathway Interaction Database (PID) is a highly structured database. It is a curated collection of 
information about known biomolecular interactions and key cellular processes assembled in to 
authoritative human signaling pathways. It includes pathways from various reliable sources such 
as NCI-Nature curated data, BioCarta data, and Reactome data. All the signature genes and the 
hallmarks were searched in the pathways and those genes found to be interacting with one 
another were noted down. The Figure 4-40 below shows the interactions that were derived from 
PID. The genes that are colored are the Hallmarks and the genes without colors are the signature 
genes. All the interactions extracted from NCI shown below were also confirmed to be a part of 





Figure 4-40: Interactions among 31 genes and the 8 hallmarks extracted from NCI pathways and all of them 
are confirmed with the interactions from implication networks 
 
4.5.5 PubMed interactions 
PubMed was developed at the National Library of Medicine (NLM) which was located at the US 
National Institutes of Health (NIH). It was developed by National Center for Biotechnology 
Information (NCBI). It is a search engine which includes accesses to many databases in the field 
of medicine and related disciplines. It also holds the links to an enormous number of citations, 
abstracts, journals and full text articles. The signature genes and the hallmarks were searched in 
PubMed and their interactors were noted if they were present among the signature genes or the 
hallmarks. The Figure 4-41 below shows the interactions between the signature genes and the 
Hallmarks. The genes that are colored are the Hallmarks and the genes without colors are the 
signature genes. All the interactions extracted from PubMed shown below were also confirmed 





Figure 4-41: Interactions among 31 genes and the 8 hallmarks extracted from PubMed and all of them are 
confirmed with the interactions from implication networks 
 
4.5.6 Matisse 
Matisse stands for Modular Analysis via Topology of Interactions and Similarity Sets. It is a 
software program for detecting the functional modules present in a set of data. It uses an 
interaction network which has already been generated from trustworthy sources. It acts as a tool 
to identify sets of genes that are highly correlated and also connected sub graphs in networks. 
The species was selected as Homo sapiens. An interaction network for human genomes (pre 
generated) was loaded. The gene expression file of the Training dataset for the 31 gene signature 
along with the hallmarks was loaded and the program was ran which detects the nodes and edges 
(6214 and 25086 respectively) of the interaction network and expression patterns and conditions 
(39 and 256) of the dataset loaded. New Modules were found using different algorithms like 
Matisse and Expression k-means. The minimum seed and module sizes were varied between 1 
and 5. Correlation coefficients were found using one of the various methods such as Dot product 
(Pearson), Euclidean distance, Spearman correlation, and Partial correlation. The modules 
contained many genes which were not present in the 31 gene signature and so they were ignored. 




the Figure 4-42 below. All the interactions extracted from Matisse shown below were also 
confirmed to be a part of the implication networks. 
 
Figure 4-42: Interactions among 31 genes and the 8 hallmarks extracted from MATISSE and all of them are 
confirmed with the interactions from implication networks 
 
4.5.7 STRING 8 
STRING stands for Search Tool for the Retrieval of Interacting Genes/Proteins. It is web based 
tool used to extract the protein-protein interactions between the set of genes that were input to it. 
It also includes interactions from various other sources such as MINT, HPRD, BIND, DIP, etc. 
other than the interactions that were extracted from its algorithm.  
The 31 genes along with the 8 hallmarks were input to STRING. It identified all the genes from 
its database in various species and generates a list where the most probable species was 
highlighted at the top of the list. Once the species was selected, it gave a list of aliases for each of 
the genes with the most important one highlighted. Some genes might not be found in its 
database. After the required genes were selected, it generated a figure of the network that was 
generated using medium confidence of 0.4 as a default value. The evidence view of the network 
generated is shown in the Figure 4-43 below. Each color in the interactions corresponds to a 
different source as shown in Figure 4-44. All the interactions extracted from STRING shown 
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Figure 4-45: List of the input genes (among 31 gene signature) that were identified by STRING 8 and were 
displayed at the output 
 
4.5.8 Ingenuity Pathway Analysis 
When the 31 genes along with the 8 hallmarks were input in to IPA, it generated five networks 
that were significant. The networks contained not only the genes from the signature but also 
those that that played an important role in the network. The five networks are shown below in the 
Figures 4-46 to 4-50.  
The first network shown in Figure 4-46 had 33 molecules and is associated with Network 
Functions such as Cancer, Cellular Growth and Proliferation, and Hematological Disease. The 
second network shown in Figure 4-47 is associated with Network Functions such as Cancer, Cell 
Cycle, and Cellular Development. The third network shown in Figure 4-48 is associated with 




Connective Tissue Development and Function. The fourth network shown in Figure 4-49 is 
associated with Network Functions such as Infection Mechanism, Cancer, and Hepatic System 
Disease. The fifth network shown in Figure 4-50 is associated with Network Functions such as 
Infection Mechanism, Gene Expression, and Cancer. 
There are a lot of Bio Functions under the Diseases and Disorder, Molecular and Cellular 
Functions, Physiological System Development and Function that were found from the signature 
which had very significant p-values. There were also Canonical Pathways, Tox lists, and Tox 
Functions which were significant.  
 
Figure 4-46: Network 1 generated from IPA 
 
 






Figure 4-48: Network 3 
generated from IPA 
 
Figure 4-49: Network 4 
generated from IPA 
 
 
Figure 4-50: Network 5 
generated from IPA 
When all the five networks were merged to form a big network, it had two types of connections. 
The highlighted interactions between the genes were the inter network connections that did not 
exist in the five networks shown above. They were emerged just because of the merging. This 





Figure 4-51: Merged network from all the 5 networks shown above where grey connections are the intra-
network connections and orange connections are inter-network connections in IPA 
 
All the interactions involving the 31 genes signature and the 8 hallmarks only were separated. 
These interactions were confirmed to be present in the implication network. These interactions 
are shown in the Figure 4-52 below. Each node is of different shape and the legend explains the 
meaning of each of the shapes. The solid lines represent the direct interactions and the dotted 





Figure 4-52: Interactions between the 31 genes and the 8 cancer hallmarks extracted from the merged 




The 31 genes signature and the 8 hallmarks were input to Pathway Studio. All the genes except 
215642_at and 217470_at were found. Hence the signature contained only 29 genes which were 
fed into Pathway Studio. It generated a network as shown below in Figure 4-61. There were 
numerous interactions in between a pair of genes which indicate that different kinds of 
relationships were found between those genes from different sources. All the interactions shown 





Figure 4-53: Interactions between the 31 genes and the 8 hallmarks that were extracted from Pathway studio 
where each kind of line represents different kinds of relationships between the genes 
 
4.6 Summary  
This chapter provided the results that were obtained from the performed analyses. Thus the 
number of interactions of implication networks and Bayesian networks, in different datasets for 
the 31 gene signature in each of the groups are concluded below in Table 4-29. It can be seen 
that the implication networks were able to detect many more gene/protein interactions when 




Table 4-29: Comparison of number of interactions from Poor and Good Prognosis of each dataset generated 
in Implication Networks and Bayesian Networks (using Tetrad IV) 
  IMPLICATION NETWORKS TETRAD IV (BAYESIAN)
TRAINING GOOD PROGNOSIS 897 13 
TRAINING POOR PROGNOSIS 1021 13 
DFCI GOOD PROGNOSIS 938 12 
DFCI POOR PROGNOSIS 787 14 
MSK GOOD PROGNOSIS 996 13 
MSK POOR PROGNOSIS 992 14 
 
The interactions among the 31 genes extracted from different tools were compared with the 
interactions obtained from implication networks and Bayesian networks as concluded in Table 4-
30. It can be seen that the interactions from all the tools were present in implication networks but 
most of them did not show up in Bayesian networks. 
Table 4-30: Comparison of number of interactions among the 31 genes and the 8 hallmarks identified from 










The interactions from implication networks and Bayesian networks were input in to Prodistin 
and the biological processes they are involved are noted down along with the number of 
significant processes. It can be seen from Table 4-31 that interactions from Bayesian networks 
did not show any biological processes. On the other hand, interaction from implication networks 




Table 4-31: Number of Biological Processes identified using Prodistin when interactions from implication 
networks and Bayesian networks are given as input. 
 IMPLICATION NETWORKS  TETRAD IV (BAYESIAN) 
TRAINING GOOD PROGNOSIS 14(3 SIGNIFICANT) 0 
TRAINING POOR PROGNOSIS 7(2 SIGNIFICANT) 0 
DFCI GOOD PROGNOSIS 4 0 
DFCI POOR PROGNOSIS 2 0 
MSK GOOD PROGNOSIS 11 (3 SIGNIFICANT) 0 
MSK POOR PROGNOSIS 11 0 
 
To increase the possibility of biological relevance and to reduce the false discovery rate, 
thresholds can be applied on the weight functions of the implication rules. For the results in 
Table 4-29, no thresholds were applied and hence there were a large number of interactions. We 
applied a threshold on the weight functions (equations 2.17 and 2.18) to reduce the number of 
interactions that would remain along with all the interactions from curated databases. The 
weights are variables between [0, 1]. The thresholds w1≥0.539474 and w2≥0.333333 made all 
the interactions from curated databases remain in the implication networks. For these applied 
thresholds, the number of interactions that remain in each of the datasets in Poor and Good 
prognosis are summarized in the Table 4-32 below. A few intermediate calculations of threshold 
on weights are also shown in the table below. 
Table 4-32: Comparison of number of interactions from Poor and Good Prognosis of each dataset in 












TRAINING GOOD PROGNOSIS 897 761 619 543  498
TRAINING POOR PROGNOSIS 1021 856 741 678  563
DFCI GOOD PROGNOSIS 938 886 851 772  709
DFCI POOR PROGNOSIS 787 758 706 676  605
MSK GOOD PROGNOSIS 996 949 911 849  752





The Figures below show the representation of the values in the Table above for the three datasets 
separately. Figure 4-54 shows the variation of the number of gene interactions with threshold on 
weights in the Training group. Figure 4-55 shows the variation of the number of gene 
interactions with threshold on weights in the DFCI test group. Figure 4-56 shows the variation of 
the number of gene interactions with threshold on weights in the MSK test group. 
 
 
Figure 4-54: Variation of number of gene interactions with threshold on weights in Training Group. The first 
set of data is the number of interactions without any thresholds and the fifth set of data is the number of gene 
interactions with the given thresholds which include all the curated interactions. The second, third and fourth 
set of data are intermediate set of results to show how the number of gene interactions decrease with an 














































Figure 4-55: Variation of number of gene interactions with threshold on weights in DFCI test Group. The 
first set of data is the number of interactions without any thresholds and the fifth set of data is the number of 
gene interactions with the given thresholds which include all the curated interactions. The second, third and 
fourth set of data are intermediate set of results to show how the number of gene interactions decrease with 
an increase in thresholds. 
 
Figure 4-56: Variation of number of gene interactions with threshold on weights in MSK test Group. The first 
set of data is the number of interactions without any thresholds and the fifth set of data is the number of gene 
interactions with the given thresholds which include all the curated interactions. The second, third and fourth 
set of data are intermediate set of results to show how the number of gene interactions decrease with an 




















































































This chapter thus summarizes that the 31 gene signature that has been identified using 
implication networks and interactions with hallmarks is a good predictor. It also summarizes that 
the model used for generating the 31 gene signature is also very good in detecting more 







This chapter describes the implementation of the package which was used to perform the 
analyses. The package is a combination of C and R where C-code was made to run through the 
R-interface. This chapter also describes the different versions of the code available and the 
changes between them. It also gives a few screen shots of the implementation of the package and 
the configuration of the computer used to run the code. 
5.2. Description 
All the code was implemented in C. It was compiled at the command prompt to create the .dll 
(dynamic linked library) file. After the compilation, the .dll file was loaded in to R. In R, the 
code needed 4 filenames as input. Two of these filenames correspond to the files that were given 
as input while the other two file names were the names of the output files that were created while 
the code executed and the final output was stored. After the execution was over the .dll file that 
was loaded initially had to be unloaded to avoid errors in the later executions. The first of the 
input files contains the micro array data of patients profile gene expression values of all the 
genes along with their gene symbols and the survival time and status at the end of the file. The 
second file is the list of the hallmarks that were used. The two output files contain the genes that 
interact with all the hallmarks, one file for each of the groups. 
There are two versions of the C-codes. Both of them work in the above mentioned manner. But 




First version of the code generates the entire genome wide interactions and keeps storing them in 
the hard disk of the computer while generating. It takes time as there are a lot of memory read 
and write operations. The second version of the code generates only the interactions between the 
genes and the hallmarks ignoring all the interactions that do not contain at least one of the 
hallmarks. This code does not require more memory as it uses linked lists and stores the 
interactions in the cache. Thus it is much faster than the first version. 
It required around 40 minutes for executing the first version of the package through R. The 
second version required around 25 minutes. The codes were executed on a system with the 
following configuration: The processor was an Intel® CoreTM2 Duo CPU E8300 @ 2.83GHz. 
There was 4.00GB of Memory (RAM) in the system. The C drive was allocated with 455GB of 







Figure 5-1: Changing the directory to the current directory and compiling the C-code to generate the 
required dynamic linked library files to be used for executing code in R 
 
 






Figure 5-3: Main difference between the C-codes shown in the second version of the code 
 
 
Figure 5-4: Output from R: Red lines are the input code and the next blue lines are the outputs after 





From the Figure 5-1 shown above, it can be seen that compiling the C-code was done first at the 
command prompt and then Figure 5-4 shows the statements to be executed to run the package. 
Figures 5-2 and 5-3 show parts of the C-code in the two versions of the package available. 
5.4. Summary 
This chapter thus shows the screenshots of the C-code. It also describes the differences in the 
various versions of the code. The C-code which executes the required process was thus 
embedded in to R to form a package which automated the process of finding good prognostic 







Identifying the critical genes in a network would help in predicting cancer recurrence. Thus a 
novel network based methodology was developed which overcame the limitations of feature 
selection techniques. It was thus concluded that network-based techniques are capable of finding 
accurate and stable signatures when compared to the feature selection methods. They (network-
based techniques) considered the performance of the gene interactions instead of the behavior of 
individual genes.  
It was also seen from that implication networks are better than the currently used network-based 
techniques such as the correlation coefficient based and clustering based coexpression networks, 
Bayesian networks, and Artificial neural networks. Implication networks integrate formal logic 
and statistics and are thus very efficient. They also overcome the limitations of the currently used 
network-based techniques. Comparison of the Bayesian networks was done practically in chapter 
4 from which it can be concluded that the prediction logic induced implication networks were 
much better in finding more gene/protein connections when compared to the Bayesian networks. 
The implication network was another kind of coexpression network which was built using 
predication logic. Prognostic signatures were identified from the genome wide coexpression 
networks based on the interactions with major cancer hallmarks (E2F, EGF, EGFR, KRAS, 




network, it was evaluated prognostically, clinically and structurally to make sure that the 
obtained signature was significant.  
The Prognostic validation showed that the signature was significant with the help of KM plots, 
log-rank p-values, CPE values, and FDR from GSEA. The model was also compared to other 
classification methods from Weka. It was found that the Cox model on implication networks was 
much better in classifying the instances. Clinical evaluation was performed using multivariate 
Cox model with respect to other clinical factors. The signature was highly significant when 
compared to other predictors.  
Structural validation was done by checking the interactions from implication networks with the 
interactions from Bayesian networks generated by Tetrad IV. It was seen from various web 
based tools that the implication networks were able to generate many more gene/protein 
interactions with biological relevance when compared to Bayesian networks. Weights of the 
implication rules were also tuned to increase the possibility of biological relevance and decrease 
the false discovery rates. These weights were tuned in such a way that they still include all the 
interactions from the curated databases. Thus all the validation methods have concluded that the 
signature was good. Thus the implication networks help us in finding the functional clustering 
between genes. 
Thus it can be concluded that implication networks lead us to identify better down streamed 






A lot of prospective work can be done using this approach.  
New signatures are being found using other predictive factors like Smoking status of the patients.  
This network generation approach can also be tried with other cancers such as breast cancer, 
colon cancer, etc. Cross validation can be performed by using the signatures found in one kind of 
cancer to validate using datasets of other kinds of cancers. Different models can be tried with 
slight changes in the network generation. 
In this thesis, only one set of expression values have been used to build the implication networks. 
But implication networks actually have the potential to model dynamic networks with temporal 
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